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ABSTRACT 
 
A series of the Baylis-Hillman adducts have been obtained by reacting protected O-
benzylated and unprotected substituted salicylaldehydes with methyl acrylate or tert-
butyl acrylate, respectively, using DABCO as catalyst. Treatment of the Baylis-Hillman 
adducts with HCl in a mixture of acetic acid and acetic anhydride afforded the 
corresponding 3-(chloromethyl)coumarin derivatives with yields of up to 94%. Similar 
use of HI afforded the corresponding 3-(iodomethyl)coumarins but, depending on the 
reaction time, the reduced 3-methyl analogues could also be obtained. 
 
Arbuzov reactions of the 3-(halomethyl)coumarin derivatives have been undertaken to 
afford 4-phosphorylated and 1’-phosphorylated derivatives, regioselectivity being 
dependent on the halide-leaving group. The 3-(chloromethyl)coumarin derivatives have 
been subjected to nucleophilic (SN) attack by benzylamine to give the corresponding 3-
[(benzylamino)methyl]coumarin derivatives in yields of up to 74%. Further treatment of 
the 3-[(benzylamino)methyl]coumarin derivatives with chloroacetyl chloride afforded the 
chloroacetamide derivatives, which exhibit hindered rotation about the amine C(O)-N 
bond. The acetamide derivatives have also been subjected to Arbuzov reaction conditions 
to afford the phosphorylated derivatives in yields of up to 86%. 
 
In a preliminary modelling study, hydrolysed analogues of the synthesized 
phosphorylated derivatives have been docked into the active site of the HIV-1 protease 
enzyme using the Cerius-2 Ligandfit software module to provide an insight into potential 
receptor-ligand hydrogen bonding interactions.  
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1. INTRODUCTION 
 
 
1.1. A brief overview of HIV/AIDS 
 
The Human Immunodeficiency virus (HIV) is a retrovirus that causes Acquired 
Immunodeficiency Syndrome (AIDS). The virus has a single-stranded RNA genome 
which replicates to double stranded DNA by a catalytic reverse transcriptase. A unique 
feature of HIV is that the virus first attaches to the surface of the T-helper lymphocyte 
cells via glycoprotein120 (gp120) before infecting them. These cells play a crucial role in 
the immune system by coordinating the action of the rest of the immune system. The 
virus uses the energy and the nutrients of lymphocyte cells to make copies of itself before 
destroying the cell. The reduction in the number of the T-helper cells seriously weakens 
the immune system.1,2 
 
Today, AIDS remains a serious health problem worldwide. In December 2006 it was 
estimated that 3.6–6.6 million people were suffering from HIV/AIDS. While more than 
2.9 million had died since the beginning of that year and an estimated 4.3 million are 
infected every year.3   
 
1.2. Structure of HIV-1  
A schematic drawing of the matured virion is shown in Figure 1.4 The shape of virion is 
spherical and its length is about 100 nm.5  
 
 
 
Figure 1. Schematic drawing of the mature virion4 (re-produced by permission). 
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The virion consists of nine genes; the gap, pol and env genes have the necessary 
information required to produce structural protein, while the tat, rev, nef, vif, vpr and vpu 
genes are responsible for reproduction of the virus and infecting the host cells. The virion 
has a bilayer membrane that is derived from the infected host cell. The outer surface is 
surrounded by many little spikes, comprising glycoproteins (gp120) that are anchored to 
the transmembrane protein (gp41). The glycoprotein plays an important role in the entry 
of the HIV into the host cell. The conical capsid located at the centre of the virion 
contains the genetic material. Two copies of the viral RNA genome are within the capsid, 
which also contains the three enzymes essential for HIV replication, viz., reverse 
transcriptase (RT), protease (PR) and integrase.5,6,7 
 
 
1.3. Life cycle of HIV-1 
 
Once HIV enters the body, it attaches to the CD4 receptors [via glycoprotein 120 
(gp120)] and other co-receptor cells within the system, allowing the HIV-1 to fuse into 
the cell and release genetic RNA and essential enzymes.7,8 The HIV-1 enzyme, reverse 
transcriptase, transcribes the single-stranded RNA into a double-stranded viral DNA 
molecule, which migrates into the host-cell nucleus where it is integrated into the host 
genome by the enzyme, integrase. The proviral DNA is transcribed into mRNA and the 
viral proteins are produced in the cytoplasm. Finally, the enzyme, protease (PR), cleaves 
viral polyproteins to afford mature proteins, permitting budding and release of new 
virions so spreading the disease. 8,9,10,11 
 
1.4. The current strategies for HIV-1 treatment  
 
A number of anti-viral therapies have been developed, but the problems of drug 
resistance and cross-resistant mutants remain. There are several HIV inhibitors, which 
work by interfering with different stages of the life cycle of the virus; these include 
fusion or entry inhibitors, 12 protease inhibitors (PIs) 9,13 and reverse transcriptase 
inhibitors (RTIs).14,15 The fusion inhibitors work by binding to HIV glycoprotein 120, 
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which prevents fusion with the cell. The RTIs are used to inhibit the viral reverse 
transcriptase needed to convert viral RNA to DNA. At present several RTIs have been 
developed and are in clinical use. The main classes of RTIs are nucleoside reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTI).  
 
A numbers of HIV-1 protease inhibitors are currently available. These compounds 
prevent cleavage of long polypeptide chains and formation of new virions. The PIs work 
by binding to the active site of HIV-1 protease. At present, the Food and Drugs 
Administration (FDA) in the United States have approved seven drugs as inhibitors for 
HIV-1 PR.  
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FDA approved HIV-1 protease inhibitors with their inhibition potentials (Ki).  
 
 
In 1995, Saquiniavir was approved by the FDA.16,17 This was followed by Indinavir 21 in 
1996, Nelfinavir 19,20 in 1997, Amprenavir 16 in 1999 and Lopinavir 22 in September 2000. 
The latest HIV-1 protease inhibitor, Atazanavir 23 was developed by Boehringer 
Ingelheim and was approved by the FDA in 2003. Although these inhibitors are now 
available, there is still a demand for new HIV-1 protease inhibitors because the present 
inhibitors have undesirable side effects and the virus is beginning to develop resistance to 
them.   
  
1.5. HIV-1 protease enzyme 
 
By definition, HIV-1 protease is an enzyme that cleaves long polypeptide chains into 
smaller proteins, which are essential for the formation of new HIV virions. The HIV-1 
protease enzyme (HIV-1 PR) is a homo-dimer containing two identical polypeptide 
chains of 99 amino acids each. Aspartyl residues are involved in the cleavage mechanism 
and, hence, the protein is an aspartyl protease enzyme. HIV-1 protease has one active 
site, and the structure of the enzyme is shown in Figure 2. 
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Figure 2. Structure of HIV-1 protease enzyme25 (re-produced by permission). 
 
The active site is located at the base of the receptor cavity and contains two essential 
aspartyl residues (Asp-25 and Asp-25’). The cavity is surrounded by two flexible flaps, 
which are involved in substrate binding and product release. These flaps contain two 
isoleucine residues, Ile-50 and Ile-50’, which interact through hydrogen bonding with an 
activated water molecule. 10, 24, 26 
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 Figure 3. Schematic representation of HIV-1 PR with a water molecule binding a 
peptide substrate via two hydrogen bonds.10 
 
 
The water molecule at the base of the receptor cavity is responsible for binding the 
substrate as shown in Figure 3. HIV-1 protease has sub-sites, which are mostly 
hydrophobic, and structurally equivalent and these are identified by the symbols, S1, S 1, 
S2, S 2 etc.).10,24,26 
 
The synthetic HIV-1 protease inhibitors need to fulfil the following design criteria; they  
must: - i) be non-cleavable; ii) be capable of bonding to the aspartyl residues and the 
structural water molecule; iii) be hydrophobic; and iv) should exhibit low Ki values.27,28 
 
1.6. Different compounds with anti HIV-1 activity  
 
The investigation of libraries aimed at finding inhibitors of HIV-1 protease led to the 
discovery of 2-hetero-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid 
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derivatives.29 Compound A with a benzimidizole moiety at the P3’-subsite has been 
shown to inhibit the protease enzyme with inhibitory activity (Ki) of 3nM and anti-viral 
activity (IC50) of less than 30nM. However, uptake of compound A by animals shows low 
oral bioavailability.  The challenge to increase oral bioavailability led to the discovery of 
compound B, which was achieved by introducing 1(S)-amino-2(R)-hydroxyindane at the 
C-terminus of the inhibitor. Compound B also exhibits improved anti-viral activity (IC50 
< 242nM).  
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The aim of keeping oral activity while improving anti-viral activity led to the 
development of the peptidomimetic inhibitor C containing ether–type macrocycles.  
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Compound C has been found to have good anti-HIV-1 PR activity (IC50 < 21nM) without 
affecting the oral bioavailability.   
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               Compound D                                                  Compound E  
 
Further investigation led to the discovery of compounds containing a 3-substituted-4-
hydroxycoumarin moiety, such as warfarin D19 and phenprocoumon E30. However, 
compound D is waekly active against HIV-PR. The phenprocoumon E, however, is more 
active against the protease enzyme with an inhibition potential of 1 µM. The hydroxyl 
group on phenprocoumon E has the potential to hydrogen-bond with the catalytic aspartic 
residues, while the carbonyl group of the coumarin nucleus hydrogen-bonds with the Ile-
50 residue of protease enzyme. 
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1.7. A brief overview of coumarins and their biological activity 
 
Compounds containing the coumarin moiety (2H-1-benzopyran-2-one) 1 constitute an 
important class of heterocycles, many examples of which are found in nature. Coumarin 
itself was first isolated in 1822 from the tonka bean.31 Coumarin and its derivatives have 
been isolated from sweet clover, bison grass and woodruff.32,33 
 
             
OO
                             
O OOH
              
                                         
               Coumarin 1                                           Umbelliferone 2 
 
 
Coumarins can be divided into four sub-types: i) simple coumarins which are 
hydroxylated, alkoxylated or alkylated on the benzene ring (e.g. umbelliferone 2);32,34 ii) 
Furanocoumarins, which contain a five-membered furan ring attached to the coumarin 
moiety and which are sub-divided into the linear furanocoumarins (e.g. xanthotoxin 3) 
and the angular furanocoumarins (e.g. angeligin 4);32,35 iii) pyranocoumarins, containing 
a six-membered ring attached to the coumarin moiety (e.g. seselin 5 and xanthyletin 
6);32,36 and iv) coumarins with substituents in the pyrone ring (e.g. warfarin 7).37 
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Many compounds containing a coumarin moiety have also been found to exhibit useful 
and multi-biological activities, including anti-inflammatory,38 antifungal,39 
antimicrobial40 and anti-HIV properties.36 As indicated earlier, 4-hydroxycoumarin 
derivatives,42 have the potential to hydrogen-bond via the 4-hydroxyl group with the 
catalytic aspartic residues in the HIV-1 protease active site. 42 
 
1.8. Some naturally occurring coumarins 
 
Warfarin 7 is a naturally occurring compound containing the 4-hydroxy coumarin moiety. 
It has been isolated from woodruff as well as from lavender and is used to prevent clotting 
of blood in the veins, lungs or heart.43,44 Another well-known natural compound 
containing the coumarin nucleus is 7-hydroxycoumarin, also known as umbelliferone 2,45 
which is found in a variety of plants, such as carrots, coriander and garden angelica. It 
has been used as a sunscreen, a fluorescence indicator and as a dye indicator.45,46,47 
Dicoumarol 8 is another natural occurring compound containing the coumarin nucleus, 
and is known for causing sweet clover disease in cattle.48,49 It has been isolated from 
sweet clover hay and used as an anticoagulant.50 
 
Many synthetic compounds, which contain the coumarin moiety, are well known for their 
odour, stability to alkali, and availability. They are widely used in perfume, soaps and 
detergents.51 Coumarin was once used as a food flavourant, but was banned by the FDA 
due to carcinogenicity.52  
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1.9. Methods of coumarin synthesis 
 
Because of their varied biological activities, the preparation of coumarin and its 
derivatives has attracted the attention of organic chemists. Numerous methods have been 
developed for the their synthesis, including the Pechmann condensation,53,54 the Perkin 
reaction,55,56 the Knoevenagel condensation,57,58 the Wittig reaction56,59 and the Baylis-
Hillman reaction.56,60,61 
 
1.9.1. Pechmann condensation 
 
In the Pechmann reaction, a substituted phenol is condensed with a β–keto ester, such as 
ethyl acetoacetate or methyl acetoacetate, under solvent-free conditions. This approach 
commonly employs heterogeneous catalysts such as HClO4.SiO2.53 The products are 
typically isolated in yields ranging from 65 to 97%. The method offers several 
advantages, viz., the low cost of the catalyst (which can be recovered), the generally high 
yield of products and fast reaction times. 
OH
O
OR'
O HClO4.SiO2 O O
R'= Et or Me
+
130oC, 30-90 Min
10 11 12
 
                                                                Scheme 2 
                                                        
Thimons et al.54 have also reported the synthesis of substituted coumarins from 
substituted phenols and ethyl acetoacetate via the Pechmann condensation, using toluene 
as solvent in the presence of acidic catalysts, such as Amberlyst IR120 or Nafion 417 
(Scheme 3). A disadvantage of this methodology, however, is the low yield of products 
obtained.  
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13 14 15
 
 
                                                                 Scheme 3 
 
1.9.2. Perkin reaction 
 
The Perkin reaction is another useful approach for the synthesis of coumarin and its 
derivatives. This reaction involves heating salicylaldehyde with acetic anhydride in a 1:2 
molar ratio using sodium acetate as catalyst at high temperature (Scheme 4). Although 
the coumarin is obtained in low yield and is accompanied by the formation of tarry 
materials, the Perkin approach does offer the advantage of not forming the isomeric 
chromene. 56 
 
H
O
OH
O
O O NaOAc
high temperature O O
+
15 16 1
 
 
                                                              Scheme 4  
 
Santana et al.55 have also reported the preparation of coumarin derivatives by reacting 
substituted salicylaldehydes with 3,5-dimethoxyphenylacetic acid using N,N’-
dicyclohexylcarbodiimide in DMSO via a Perkin-type reaction. The methoxy groups 
were then hydrolyzed using HI in acetic anhydride to give di- or trihydroxy derivatives 
with reasonable yields up to 79% as illustrated in Scheme 5. 
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                                                                Scheme 5 
                                                                         
1.9.3. Knoevenagel condensation 
 
In general, the Knoevenagel condensation reaction occurs between a substituted 
salicyladehyde and activated methylene compounds in the presence of an amine catalyst. 
However, Heravi et al.57 has reported the preparation of coumarin derivatives via 
microwave-assisted Knoevenagel reactions using 2-hydroxybenzaldehydes or 
hydroxynaphthaldehyde with malonic acid on microwave irradiation in solvent-free 
conditions (Scheme 6). The method employs the HZSM-5 zeolite as a catalyst, and 
affords isolated products in yields of up to 97%. 
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15
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19 20
 
                                                                 Scheme 6 
 
Bagdol58 has also reported the preparation of coumarins by reacting salicylaldehyde and 
its derivatives with substituted ethyl acetate via a microwave-assisted Knoevenagel 
reaction (Scheme 7). This approach employed piperidine as catalyst under solvent-free 
conditions, and offers several advantages, such as lower reaction time and high yields of 
product.   
         
H
O
OHR
R= CO2Et, H
X CO2Et
O
X
OR
piperidine
X= CO2Et, COMe, CN
microwave-assisted
+
15 21 22
 
                                                             Scheme 7 
 
 
 
1.9.4. Wittig reaction 
 
 
The Wittig reaction has also been used to synthesise coumarin derivatives.56 This 
approach involves reaction of an aromatic aldehyde or ketone with a phosphonate or 
phosphorus ylide. For example, when a substituted salicylaldehyde 15, 
triphenylphosphine and ethyl chloroacetate were reacted in the presence of MgO and 
sodium methoxide, the coumarin products were isolated in excellent yields of up to 90% 
(Scheme 8).59 
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15 20
 
 
                                                                     Scheme 8 
 
 
1.9.5. Baylis-Hillman Reaction 
 
The Baylis–Hillman reaction provides another useful approach to the synthesis of 
coumarin derivatives. Previous members of our group have applied Baylis-Hillman 
methodology in the synthesis of quinolines,62 indolizines,63 2H-1-thiochromenes60 and 
coumarins.56,60,61 This method involves C-C bond formation between an activated alkene 
and an aldehyde in the presence of a catalyst, such as DABCO, to give allylic alcohol 
products (Scheme 9).64 A common disadvantage of Baylis-Hillman methodology, 
however, is the long reaction time. It can take up to 3 weeks to obtain reasonable yields. 
 
R H
O
O
R' R
OH
R'
O
DABCO
+
21 23 24
 
        
                                                           Scheme 9 
                
Bode65 investigated the mechanism of the Baylis-Hillman reaction. A key step is believed 
to be the formation of a zwitterionic enolate species by nucleophilic addition of the 
catalyst to the double bond of the alkene; this is followed by addition of the reacting 
enolate species to the aldehyde in the rate-determining step. Proton transfer and 
elimination of catalyst then affords the Baylis-Hillman product.61 The reaction was shown 
to be first-order in the aldehyde, the alkene and catalyst and third-order overall (Scheme 
10). 
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                                                                    Scheme 10 
 
De Souza et al.66 have reported the use of hexamethylethylenetetraamine (HMT) as a 
catalyst to synthesise the Baylis-Hillman adducts (Scheme 11). HMT has been shown to 
improve the yields and reduces the time. Other tertiary amine catalysts such as DBU 29, 
quinuclidine 30 and DMAP 31 have also been applied in the Baylis-Hillman reaction 
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                                                                         Scheme 11 
     
                
N
N
                
N
N
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N
 
                DABCO 28                    DBU 29                  quinuclidine 30               DMAP 31 
 
 
Bode 65 had reported that reacting salicylaldehyde with methyl acrylate in the presence of 
DABCO didn’t give the expected Baylis-Hillman adduct but gave, instead, the coumarin 
derivative 32 (Scheme 12). Robinson,67 on re-visiting these reactions, demonstrated 
formation of various chromene and coumarin derivatives. Careful separation by flash 
column chromatography led to the isolation of eight different classes of products, e.g. 34-
38, as well as products 33 corresponding to product 32, isolated by Bode. 
H
O
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O
CHO
O
DABCO
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15 26 32
 
                                                                       Scheme 12 
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The regioselectivity of the cyclisation could be controlled to form coumarin by protecting 
the salicylaldehyde phenolic group before reacting it with the activated alkene as the 
benzyl ether.61 Treatment of the resulting benzyl ether with methyl acrylate in the 
presence of DABCO afforded the Baylis-Hillman adducts 40. The reaction of HI or HCl 
with the α,β-unsaturated adducts 40 and acid-catalysed acylation gave the desired 
coumarin derivatives 41 and 42 (Scheme 13). 
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                                                                  Scheme 13   
 
                                                                                                     
Musa68 synthesized coumarin derivatives using Baylis-Hillman methodology by reacting 
salicylaldehyde derivatives 15 and t-butyl acrylate 23 using DABCO 28 as catalyst. The 
resulting Baylis-Hillman adducts were obtained in yields of up to 60%. The Baylis-
Hillman adducts were then reacted with HCl or HI in acetic acid to form the coumarin 
derivatives. The use of HCl gave 3-(chloromethyl)coumarin derivatives 41 in good yields 
(86-90%), whereas use of HI gave the corresponding 3-(iodomethyl)coumarin derivatives 
42 with low yields (17%) as shown in Scheme 14.  
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1.10. Reactivity of coumarins  
 
Coumarin and its derivatives are highly reactive. Because the coumarin moiety is 
aliphatic, it is likely to undergo ring-opening at the acyl centre or conjugate addition at 
the carbon-carbon double bond.69,70 The carbonyl lactone group of the coumarin nucleus 
is characterized by an IR absorption band at ca.1700 cm-1.71 The presence of a methyl 
group at C-4 or C-6 makes the coumarin nucleus more reactive, and can result in the 
coumarin nucleus undergoing halogenation as well as condensation with the aldehydes.71 
Carbon-6 on the aromatic ring can undergo electrophilic attack, e.g. sulfonation or 
Friedel-crafts acylation leading  to the formation 6-substituted derivatives. Electrophilic 
attack at C-3 can only occur under forcing conditions unless a C-4 substituent, such as a 
hydroxyl group directs the incoming group to the C-3 position.72,73 The nucleophilic 
attack on the coumarin nucleus depends on the nature of the nucleophile. Thus, strong 
nucleophiles, such as secondary amines, are likely to open the ring through attack at the 
acyl centre, whereas weak nucleophiles attack the C-4 position (e.g. bromination).71 
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A methyl substituent on the coumarin nucleus may react differently, depending on the 
position of attachment. For example, a methyl group attached to C-6 or C-4 is more 
reactive than a methyl groups at the C-3 or C-5 positions.71,74 A methyl substituent on the 
pyran moiety of coumarin appears to be stable under bromination conditions whereas 
bromination is observed on the 7-methyl group attached to the benzene ring (Scheme 
15).75  
  
            
O O
OMe
O O
OMe
Br
NBS, peroxide
45 46
 
Scheme 15. Bromination of a 7-methyl group.75 
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1.11. Objectives of the present Study 
 
The proposed research formed part of a group programme aimed at preparing compounds 
that might inhibit the HIV-1 protease enzyme, and the project was expected to build on 
methodology developed by previous members of the group. Specific objectives of the 
research have included the following. 
  
1. Application of the Baylis-Hillman methodology in the synthesis of coumarin   
derivatives. 
2. Application of the Arbuzov reaction to the 3-(halomethyl)coumarin products to      
access phosphorylated derivatives. 
3. Preliminary computer modelling studies to explore binding of the synthetic    
products in the HIV-1 protease receptor cavity.   
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2. DISCUSSION. 
 
In this discussion, attention will be given to the following.  
(i) Synthesis of 3-(halomethyl)coumarin derivatives via cyclisation of O-
benzylated Baylis-Hillman products. (Section 2.1)  
(ii) Synthesis of 3-(halomethyl)coumarin derivatives via cyclisation of 
unprotected Baylis-Hillman adducts. (Section 2.2)  
(iii) Nucleophilic substitution reactions of the 3-(halomethyl)coumarin derivatives. 
(Section 2.3) 
(iv) Molecular modelling of selected structures. (Section 2.4) 
 
2.1. Synthesis of 3-(halomethyl)coumarin derivatives via cyclisation of 
O-benzylated Baylis-Hillman adducts 
 
The study was begun by demonstrating the preparation of O-benzylated Baylis-Hillman 
adducts by first protecting the salicylaldehyde phenolic hydroxyl group as a benzyl ether 
group before reacting with methyl acrylate (Scheme 16). In the research conducted by 
Musa,60 the use of a protecting group was found to afford coumarin derivatives directly 
during cyclisation of these Baylis-Hillman adducts and to inhibit the formation of 
unwanted chromene derivatives. The advantage of using ethers as a protecting group is 
that they are relatively inert but cleavable on heating with concentrated hydroiodic acid 
or hydrochloric acid.61 The formation of the known benzyl ethers was achieved by 
reacting the substituted salicylaldehydes 15a-c with benzyl bromide in the presence of 
potassium hydroxide and sodium iodide, using acetone as solvent. Chromatography on 
silica gel and work-up afforded the corresponding salicylaldehyde benzyl ethers 39a-c in 
reasonable yields of up to 54%. The salicylaldehyde benzyl ethers were analyzed by 
NMR spectroscopy. Thus, the 1H NMR spectrum of 2-benzyloxybenzaldehyde 39a 
(Figure 4) shows the two benzylic protons resonating as a singlet at 5.18 ppm and the 
aldehydic proton as a singlet at 10.52 ppm. The aromatic region shows the signals 
corresponding to the 9 aromatic protons. 
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Figure 4. 400MHz 1H NMR spectrum of benzyl ether 39a in CDCl3.  
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The 2-benzyloxybenzaldehydes 39a,b were then reacted with methyl acrylate 26 in the 
presence of a catalytic quantity of DABCO using CHCl3 as solvent.60 The mixtures were 
stirred in stoppered reaction flasks for 3 weeks to afford the corresponding O-benzylated 
Baylis-Hillman adducts 40a,b which were isolated by flash chromatography. The 
chromatographed products were obtained in low yield (< 27%) and were analyzed by 
NMR spectroscopy. The 1H NMR spectrum of the Baylis-Hillman adduct 40a (Figure 5) 
exhibits a singlet at 3.71 ppm that corresponds to the methyl signal and a broad signal at 
3.41 ppm corresponding to the hydroxy group. The two benzylic protons resonate as a 
singlet at 5.08 ppm, whereas the two vinylic protons resonate as two singlets at 5.69 and 
6.28 ppm, respectively. The singlet at 5.94 ppm corresponds to the methine proton, while 
the signals in the aromatic region correspond to the nine aromatic protons.  
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Figure 5. 400MHz 1H NMR spectrum of compound 40a in CDCl3.  
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The O-benzylated Baylis-Hillman adducts 40a,b were then treated with HCl or HI in the 
presence of acetic acid and acetic anhydride to form the 3-(halomethyl)coumarin 
derivatives as illustrated in the Scheme 16. The use of HCl gave the 3-
(chloromethyl)coumarin derivatives 41a,b in good yields of up to 83%, whereas use of 
HI gave the corresponding 3-(iodomethyl)coumarin derivatives 42a,b in yields of up to 
65% (Table 1). The 1H NMR spectrum of 3-(iodomethyl)coumarin 42a (Figure 7a) 
reveals the iodomethylene protons resonating as a singlet at 4.37 ppm, while the 
chloromethylene protons in 3-(chloromethyl)coumarin 41a resonate at 4.53 ppm (Figure 
6a). The 13C NMR spectrum of 3-(iodomethyl)coumarin 42a (Figure 7b) shows the 
iodomethylene carbon resonating upfield of TMS at -1.5 ppm, whereas  the 
chloromethylene carbon in 3-(chloromethyl)coumarin 41a resonates downfield at 40.9 
ppm (Figure 6b). Likely mechanisms for the formation of the 3-(halomethyl)coumarin 
derivatives are outlined in Scheme 17. The first step in path (a) involves conjugate 
addition of halogen acid to the α,β-unsaturated ester followed by elimination of water. 
Cleavage of the benzyl ether by the halogen acid then exposes the phenolic hydroxyl 
group, which attacks the ester group; acyl substitution then affords the coumarin. In an 
alternative pathway (b), acid-catalysed allylic displacement (SN’), followed by cyclisation 
affords the phenolic intermediate. 
OH
O
O
OBn
R :X
H
+
HX
OH2
O
O
H
XOBn
R
O
O
XOH
R
H
+
O O
X
R
[-H2O]
OH2+
O
O
OBn
R
:X
HX
[-H2O]
..
a)
b)
+
 
Scheme 17. Mechanisms for the formation of 3-(halomethyl)coumarin derivatives 41 and 
42. Path a) conjugate addition-elimination, followed by acyl substitution; Path b) SN’ 
reaction followed by cyclization. 
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Table 1. Yields obtained for the 3-(halomethyl)coumarin derivatives (Scheme 15).   
 
                                                    
                                                
O
X
O
R
 
 
                 Compounds           R                               X                 Yield/ % 
_______________________________________________________________________                        
 
                41a                         H                              Cl                     83 
                41b                      OCH2CH3                   Cl                     70    
                42a                         H                               I                       65    
                42b                      OCH2CH3                    I                       62   
________________________________________________________________________      
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Figure 6a. 400MHz 1H NMR spectrum of 3-(chloromethyl)coumarin 41a in CDCl3. 
                                                                                                                            Discussion                              
28 | P a g e  
 
ppm (t1) 0255075100125150175200
16
0.
03
2
15
3.
46
4
14
1.
12
3
13
1.
98
5
12
8.
03
1
12
4.
92
5
12
4.
68
1
11
8.
73
3
11
6.
59
7
77
.
31
8
77
.
00
0
76
.
68
2
40
.
99
3
O
Cl
O
 
 
Figure 6b. 100MHz 13C NMR spectrum of 3-(chloromethyl)coumarin 41a in CDCl3. 
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Figure 7a. 400MHz 1H NMR spectrum of 3-(iodomethyl)coumarin 42a in CDCl3. 
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Figure 7b. 100MHz 13C NMR spectrum of 3-(iodomethyl)coumarin 42a in CDCl3. 
 
                                        
2.2. Synthesis of 3-(halomethyl)coumarin derivatives via cyclisation of 
unprotected Baylis-Hillman adducts 
 
Musa and Kaye 68 have reported that the use of tert-butyl acrylate 23 as an activated 
alkene permits direct cyclisation to coumarin derivatives without protecting the phenolic 
hydroxyl group. Attention was then turned to the synthesis the Baylis-Hillman adducts 
24a-e using this approach. This was achieved by reacting the substituted salicylaldehydes 
15a-e with tert-butyl acrylate 23 in the presence of DABCO using CHCl3 as solvent 
(Scheme 18). The mixtures were stirred at room temperature for periods ranging from 5 
days to 14 days, affording the Baylis-Hillman adducts in the yields of up to 57%, after 
isolation by flash chromatography. The 1H NMR spectrum of tert-butyl 3-hydroxy-3-(2-
hydroxyphenyl)-2-methylenepropanoate 24a (Figure 8) shows the tert-butyl singlet at 
1.50 ppm, while the two vinylic protons resonate as singlets at 5.49 and 6.23 ppm, 
respectively. The methine proton resonates as a singlet at 5.69 ppm and the attached 
hydroxylic proton resonates as a singlet at 4.34 ppm. The singlet at 8.12 ppm corresponds 
to the phenolic proton.  
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                                                                        Scheme 18 
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Figure 8. 400 MHz 1H NMR spectrum of compound 24a in CDCl3. 
 
Table 2. Yields obtained for the Baylis-Hillman products 24a-e (Scheme 18). 
 
                                                   
OH
O
O
OHR
 
 
               Compound                                 R                           Yield/ %                                 
________________________________________________________________________ 
  
                     24a                                            H                                 23 
                     24b                                        3-OCH2CH3                             20    
                     24c                                        5-Cl                                 54    
                     24d                                        5-Br                                50          
                     24e                                        3-OCH3                                        25                        
______________________________________________________________________ 
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The Baylis-Hillman adducts 24a-e were then reacted under acidic conditions as outlined 
in Scheme 18. When the adducts were refluxed for 2 hours with hydrochloric acid in a 
mixture of acetic acid and acetic anhydride, the 3-(chloromethyl)coumarin derivatives 
41a-e were obtained in yields of up to 94% (pathway II). The adducts were also reacted 
with hydriodic acid under similar conditions, but for different periods of time. Refluxing 
for 2 hours resulted in a mixture of two products, which were isolated by flash column 
chromatography, viz., the expected 3-(iodomethyl)coumarin 42c and d and the reduced 3-
methyl analogues 47c and d (Scheme 18, pathway III: Figure 9). When the reaction 
mixtures were refluxed for 8 hours, the reduced analogues 47c and d were obtained as the 
sole products.  Presumably, as reaction times increase, the initial iodomethyl products are 
converted to the methyl analogues with HI acting as a reducing agent. When compounds 
24c and d were reacted for 1h, the required 3-(iodomethyl)coumarin 42c and d were 
obtained as the sole products. The 1H NMR spectrum of 6-bromo-3-methylcoumarin 47d 
(Figure 10a) reveals the methyl proton singlet at 2.20 ppm, while the spectrum of the 6-
bromo-3-(iodomethyl)coumarin precursor 42d (Figure 11a) reveals the iodomethyl signal 
at 4.53 ppm. The methyl carbon in compound 47d resonates at 17.2 ppm, while the 
iodomethyl carbon resonates upfield at -2.3 ppm (see Figures 10b and 11b), respectively. 
The DEPT135 spectrum of compound 47d confirms the methyl carbon assignment as a 
positive signal, whereas the iodomethyl signal in compound 42d is observed as negative 
methylene signal (see Figures 10c and 11c).  
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Table 3. Yields obtained for the synthesis of coumarin derivatives 42a-d and 47c-d using 
HI (Scheme 18). 
                                                                    
O O
I
R
42a-d
    
O OR
47c-d
 
______________________________________________________________________ 
Substrate      R         Refluxing period /h                    Yields of 42/ %     Yields of 47/ %     
________________________________________________________________________ 
24a               H                      2                                          60                             -                                               
24b           8-OCH2CH3         2                                          62                             -  
24c           6-Cl                     1                                           61                             -  
                                             2                                           52                            45                                        
                                             8                                           91                             -   
24d          6-Br                      1                                           58                             -   
                                             2                                           58                            43  
                                             8                                           80                             - 
________________________________________________________________________ 
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Figure 9. 400MHz 1H NMR spectrum of the mixture of 42d and 47d in CDCl3.   
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Figure 10a: 400MHz 1H NMR spectrum of 6-bromo-3-methylcoumarin 47d in CDCl3.  
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Figure 10b. 100MHz 13C NMR spectrum of 6-bromo-3-methylcoumarin 47d in CDCl3.   
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Figure 10c. DEPT135 spectrum of 6-bromo-3-methylcoumarin 47d in CDCl3. 
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Figure 11a. 400MHz 1H NMR spectrum of 6-bromo-3-(iodomethyl)coumarin 42d in 
CDCl3. 
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Figure 11b. 100MHz 13 C NMR spectrum of 6-bromo-3-(iodomethyl)coumarin 42d in 
CDCl3. 
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Figure 11c. DEPT135 spectrum of 6-bromo-3-(iodomethyl)coumarin 42d in CDCl3. 
                                                                                                                            Discussion                              
37 | P a g e  
 
 
2.3. Nucleophilic substitution of the 3-(halomethyl)coumarin derivatives  
 
A unique feature of the 3-(halomethyl)coumarin system is its potential for attack by a 
nucleophile at one or more of three electrophilic centres (C-2, C-4 or C-1’) as shown in 
Figure 12. Attack at C-2, the electrophilic carbonyl centre, may result in acyl substitution 
and ring-opening, while attack at the C-4 centre could involve either allylic substitution 
of the halide X (SN’) or conjugate addition. Displacement of a leaving group X could also 
be effected by direct (SN) substitution at C-1’.  
                              
O
X
OR
X = I or Cl
:Nu1'
2
3
4
 
Figure 12. Possible ways in which a nucleophile may attack the 3-(halomethyl)coumarin 
derivatives.                                                                                                                        
 
2.3.1 Arbuzov reactions of 3-(halomethyl)coumarin products  
 
Attention was given to the preparation of phosphonate derivatives via the Michaelis-
Arbuzov reaction as illustrated in Scheme 19.76 This synthetic approach permits the 
formation of a new C-P bond between a trivalent phosphorus reagent and alkyl halide 
derivatives.76,77,78  
 
When the 3-(chloromethyl)coumarin derivatives 41a-d were heated with two equivalents 
of triethylphosphite under solvent-free conditions in air at 120-130oC (pathway I, Scheme 
18),78 the unexpected 4-phosphorylated products 48a-d were obtained in yields of up to 
68% (Table 4), with no trace of the expected 1’-phosphorylated products 49a-d. 
Literature reviews indicate that the phosphorous group at the C-1’ position can be 
obtained when the reactions are carried out under nitrogen.78,79  The 3-
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(chloromethyl)coumarin derivatives 41a-d were therefore treated with 2 equivalents of 
triethylphosphite under the same conditions as those used in pathway I except that the 
reaction was conducted under nitrogen (pathway II). Flash chromatography of the 
isolated material afforded both 1’-phosphorylated products 49a-d in yields of up to 85% 
and the 4-phosphorylated products 48a-d in yields of up to 24%. In a similar way, 
treatment of the 3-(iodomethyl)coumarins 42a-d with 2 equivalents of triethylphosphite 
under same conditions as those described for pathway II led to formation of the 1’-
phosphorylated products 49a-d with no trace of the 4-phosphorylated analogues 48a-d 
(pathway III). A possible explanation for the formation of 48a-d and 49a-d, using 3-
(chloromethyl)coumarin derivatives 42 (pathway II) as starting material, is that chloride 
is a poorer leaving group than iodide. Therefore, the reaction rates for the chloro 
analogues are lower, permitting the incoming nucleophile (phosphorous group) to attack 
at both the C-1’ and C-4 positions, leading to the formation of the isomeric products 48a-
d and 49a-d. Also, the more electronegative Cl atom may increase the electrophilicity of 
the vinylic centre (C-4) via an electro-withdrawing inductive effect.  
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                                                         Scheme 19 
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Table 5: Yields obtained for the synthesis of 1’-phosphorylated products 48a-d and 4-
phosphorylated products 49a-d. 
                                             
O O
P
O
O
O
R
        
O
P
OO
O
OR
 
                                                        49                                          48           
________________________________________________________________________ 
Substrate         R                 X       Yields of 49/%      Yields of 48/%          Yields of 48/% 
                                                 (under N2)             (under N2)                 (in air) 
________________________________________________________________________ 
 
  41a                 H                  Cl           43                        24                             60                                       
  41b            8-OCH2CH3     Cl            85                        12                             45         
  41c             6-Cl                 Cl            55                        10                              68        
  41d             6-Br                 Cl           53                         8                               52            
  42a                 H                  I             61                          -                                -          
  42b             8-OCH2CH3     I             85                          -                                -           
  42c              6-Cl                 I             55                          -                                -           
  42d              6-Br                 I             43                          -                               -            
________________________________________________________________________ 
  
 
IR and NMR spectroscopy were used to analyse all compounds. The 1H NMR spectrum 
of diethyl (6-chloro-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48c (Figure 13a) 
shows the 3-methyl
 
group resonating as a doublet at 2.56 ppm due to coupling with 
phosphorous (JP,H = 3.2Hz). The 1H NMR spectrum of the isomeric diethyl [(6-chloro-2-
oxo-2H-chromen-3-yl)methyl]phosphonate 49c (Figure 14a) reveals a doublet, 
corresponding to the methylene protons attached to phosphorous, at 3.15 ppm with a 
large coupling constant (JP,H =  22 Hz). Furthermore, the aromatic region of the spectrum 
of compound 48c reveals the presence of three protons, while the spectrum of isomer 49c 
reveals the presence of 4 aromatic protons. The methylene protons of compound 48c 
resonate as a pair of multiplets at 4.17 and 4.25 ppm. This is attributed to the 
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Hb’ 
Ha’ 
Ha 
Hb 
diastereotopicity of the geminal protons (Ha and Hb; Ha’ and Hb’) in each methylene 
group in the preferred non-planar conformation illustrated below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equilibrium geometry calculated at the semi-empirical AM1 level. 
 
The 13C NMR spectrum of compound 48c (Figure 13b) reveals two methyl carbon signals 
as doublets at ca. 16 ppm, while the spectrum of isomer 49c (Figure 14b) reveals 
doublets corresponding to the ester- and 3-methyl carbons at ca. 16.3 and 16.5 ppm, 
respectively. The coupling between the methyl and methylene protons of the two ethoxy 
groups in compounds 48c and 49c was evident from their COSY spectra, while the 
HSQC spectra of these compounds show the correlations between protons and carbons 
(see Figures 13d, e and 14d, e respectively). The DEPT 135 of spectrum of compound 
48c supports the presence of two equivalent methylene groups coupled to phosphorus, 
whereas the methylene signals observed in the DEPT spectrum of compound 49c, reflects 
the presence of the two different types of the methylene groups; the JP,C coupling constant 
for the methylene carbon attached directly to phosphorous (resonating at ca.26 ppm) 
exhibits the larger value (JP,C = 139Hz) (see Figures 13c and 14c). The IR spectrum of 
compound 48c (Figure 13g) clearly confirms the presence of the phosphoryl (P=O) and 
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the carbonyl group (C=O) absorption bands at 1256 and 1740 cm-1, respectively, while 
the bands for the corresponding regioisomer 49c (Figure 14g) were observed at 1260 and 
1737 cm-1, respectively. The 31P NMR chemical shifts provide useful information about 
nature of the phosphorous groups in the isomers 48c and 49c. The 31P NMR spectrum of 
compound 48c (Figure 13f) shows a phosphorous signal at 13.56 ppm, while the 
phosphorous attached to an sp2 carbon resonates at 24.87 ppm in the spectrum of 
compound 49c (Figure 14f).  
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Figure 13a. 400MHz 1H NMR spectrum of compound 48c in CDCl3. 
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Figure 13b. 100MHz 13C NMR spectrum of compound 48c in CDCl3. 
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Figure 13c. DEPT135 spectrum of compound 48c in CDCl3.  
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Figure 13d. 400MHz COSY spectrum of compound 48c in CDCl3. 
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Figure 13e. HSQC spectrum of compound 48c in CDCl3. 
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Figure 13f. 162MHz 31P NMR spectrum of compound 48c in CDCl3.  
 
 
 
Figure 13g.  IR spectrum of compound 48c (nujol mull). 
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Figure 14a. 400MHz 1H NMR spectrum of compound 49c in CDCl3. 
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Figure 14b. 100MHz 13C NMR spectrum of compound 49c in CDCl3. 
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Figure 14c. DEPT135 spectrum of compound 49c in CDCl3.     
 
 
ppm (f2) 1.02.03.04.05.06.07.08.0
O O
Cl
P O
O
O
 
 
Figure 14d. 400MHz COSY spectrum of compound 49c in CDCl3. 
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Figure 14e. HSQC spectrum of compound 49c in CDCl3. 
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Figure 14f. 162MHz 31P NMR spectrum of compound 49c in CDCl3. 
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Figure 14g. IR spectrum of compound of compound 49c (nujol mull). 
 
 
 
The expected mechanism for the formation of the 4-phosphorylated products 48 is 
outlined in Scheme 20. The first step is believed to involve conjugate addition of P(OEt)3 
to the α,β-unsaturated carbonyl system, followed by displacement of halide, resulting in 
the formation of a phosphonium intermediate 51. The halide ion then attacks one of the 
O-ethyl groups in an SN reaction, and rearrangement of the double bond then affords the 
3-methyl derivatives 48 in what is effectively an allylic Arbuzov reaction. However, the 
possibility of the allylic displacement of Cl- by P(OEt)3 in an SN’ reaction to give the 
intermediate 51 in the one step cannot be excluded. 
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Scheme 20: Mechanism for the formation of the 3-methyl derivatives 48.65,66  
 
 
The formation of the 1’-phosphorylated systems 49, on the other hand, is expected to 
involve the ‘normal’ Arbuzov pathway illustrated in the Scheme 21. This reaction 
proceeds via an SN mechanism in which the alkyl halide is attacked by nucleophilic 
P(OEt)3 resulting in the formation of a phosphonium salt intermediate 52. The halide ion 
then attacks one of O-ethyl groups of the phosphonium intermediate to afford the 1’-
phosphorylated derivatives 49.81  
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Scheme 21: Mechanism for the formation of the phosphorylated derivatives 49.81 
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2.3.2. Synthesis of 3-[(benzylamino)methyl]coumarin derivatives  
 
 
C-N bond formation is one of the fundamental transformations in organic chemistry.81 
Generally the reaction of an alkyl halide with a primary amine is a widely used approach 
for the preparation of the secondary amines.78,81,82 The nucleophilic amine attacks the 
alkyl halide leading to the formation of a secondary amine. Heating or simply stirring in a 
suitable solvent, depending on the amine used, can achieve the reaction. In the present 
study, the 3-(chloromethyl)coumarin derivatives 41a-e were reacted with benzylamine 
using THF as solvent as shown in Scheme 22.81 The mixtures were stirred at room 
temperature in a stoppered reaction flask for 4 hours and after evaporation of the solvent 
in vacuo, the 3-[(benzylamino)methyl]coumarin derivatives 53a-e were isolated by flash 
chromatography. The products were obtained in yields of up to 74% (Table 6).  The 1H 
NMR spectrum of 3-[(benzylamino)methyl]coumarin 53a (Figure 15a) shows a broad 
signal at 1.99 ppm corresponding to the amino proton while the two methylene groups 
resonate as singlets at 3.74 and 3.84 ppm. The 13C NMR spectrum reveals the two-
methylene carbon signals at 53.2 and 48.4 ppm and the carbonyl carbon signal at 161.4 
ppm (Figure 15b). 
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                                                                Scheme 22 
 
Table 6. Yields obtained for the 3-[(benzylamino)methyl]coumarin derivatives 53a-e. 
    
                                              
O
N
H
OR
 
 
    Compound                                        R                                        Yield/ % 
________________________________________________________________________ 
 
          53a                                                   H                                               74 
          53b                                                8-OCH2CH3                                                 61        
          53c                                                 6-Cl                                             64  
          53d                                                 6-Br                                            35  
          53e                                                 8-OCH3                                       73               
________________________________________________________________________ 
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Figure 15a. 400MHz 1H NMR spectrum of compound 53a in CDCl3. 
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  Figure 15b. 100MHz 13C NMR spectrum of compound 53a in CDCl3.    
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2.3.3. Synthesis of chloroacetamide derivatives  
     
The 3-[(benzylamino)methyl]coumarin derivatives 53a-d were then reacted with 
chloroacetyl chloride 54 using THF as solvent (step II, Scheme 22). The mixtures were 
refluxed under nitrogen for 45 minutes to afford the amide derivatives 55a-d in yields of 
up to 72%. NMR and IR spectroscopy were used to characterize the chloroacetamide 
derivatives 55a-d. However, the 1H NMR and 13C NMR spectra were complicated by the 
presence of additional signals. These were attributed to hindered rotation about the C-N 
amide bond. When samples were run at 50oC, the signals began to broaden and then 
coalesce because the internal rotation became fast relative to the NMR time-scale. The 
resistance to rotation about the C-N bond arises from the delocalisation illustrated in 
Figure 16; the partial double-bond character of the C-N bond presents a barrier to internal 
rotation. Nuclei in different environments about the amide group may then exhibit 
different chemical shifts. At higher temperature, the internal rotation rate increases and 
the signals begin to broaden and then coalesce.83,84,85 
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Figure 16. Resonance in the amide system resulting in the partial double-bond character 
of the C-N bond.85 
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Table 7. Yields obtained for the N-benzyl-2-chloro-N-[(2-oxo-2H-chromen-3-yl)methyl]-
acetamide derivatives 55a-d. 
   
                                       
O
N
O
Cl
OR
1
2
4
3'
1'''
2'''
1''
 
 
  Compound                                         R                                       Yields/ % 
_____________________________________________________________________ 
     55a                                                    H                                                64  
     55b                                                 8-OCH2CH3                                  72   
     55c                                                 6-Cl                                               70 
     55d                                                 6-Br                                              56 
____________________________________________________________________ 
 
The 1H NMR spectrum of chloroacetamide 55d in DMSO-d6 at 30oC (Figure 17a) 
exhibits two singlets at 4.59 and 4.71 ppm corresponding to the 1”-methylene protons 
and two singlets, corresponding to the 3’-methylene protons, at 4.27 and 4.37 ppm 
reflecting the presence of rotamers. The chloromethylene protons resonate as overlapping 
singlets at 4.58 ppm. But these signals coalesce at 100oC; the 1”-methylene group 
resonates at 4.39 ppm whereas the 3”-methylene group resonates at 4.63 ppm. The 13C 
NMR spectrum (Figure 17c) and the DEPT 135 of compound 55d (Figure 17d) clearly 
illustrate the presence of additional signals due to the presence of the rotameric products. 
The IR spectrum of compound 55d clearly reveals the absorption bands of the two 
carbonyl groups (C=O) at 1660 and 1723 cm-1 (Figure 17h). Although complicated by the 
presence of signals corresponding to both rotamers, the COSY, HSQC and HMBC 
spectra were consistent with the assigned structures (Figure 17e-g). 
 
                                                                                                                            Discussion                              
55 | P a g e  
 
ppm (f1) 1.02.03.04.05.06.07.08.0
7.
95
3
7.
94
9
7.
80
5
7.
76
7
7.
74
7
7.
74
4
7.
73
3
7.
72
9
7.
39
2
7.
38
8
7.
37
7
7.
37
4
7.
36
0
7.
32
3
7.
31
0
7.
30
2
7.
29
8
7.
29
1
7.
25
5
7.
24
3
4.
71
4
4.
59
1
4.
58
7
4.
36
6
4.
27
4
3.
33
8
2.
50
0
1
.00
0
.59
3
.29
9
.34
1
.23
5
.06
1
.91
1
.10
O
N
O
Cl
O
Br
 
Figure 17a. 400MHz 1H NMR spectrum of compound 55d in DMSO-d6 at 30oC. 
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Figure 17b. 400MHz 1H NMR spectrum of compound 55d in DMSO-d6 at 100oC.  
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Figure 14c. 100MHz 13C NMR spectrum of compound 55d in DMSO-d6.  
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Figure 17d. DEPT135 spectrum of compound 55d in DMSO-d6.  
 
                                                                                                                            Discussion                              
57 | P a g e  
 
ppm (t2) 4.05.06.07.08.0
O
N
O
O
Br Cl
 
 
Figure 17e. 400MHz COSY spectrum of compound 55d in DMSO-d6. 
 
ppm (t2) 3.04 .05.06.07.08.09.0
O
N
O
O
Br C l
 
 
Figure 17f. HSQC spectrum of compound 55d in DMSO-d6. 
                                                                                                                            Discussion                              
58 | P a g e  
 
ppm (f2)
2.03.04.05.06.07.08.0
O
N
O
Cl
O
Br
 
 
Figure 17g. HMBC spectrum of compound 55d in DMSO-d6. 
 
 
 
Figure 17h. IR spectrum of compound 55d-(nujol mull).\ 
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2.3.4. Arbuzov reactions of chloroacetamide derivatives 
 
The chloroacetamide derivatives 55a-d were then reacted with 2 equivalents of triethyl 
phosphite in Michaelis–Arbuzov reactions (pathway III, Scheme 22).78,79 The mixtures 
were heated under nitrogen at 120-130oC. Isolation by flash chromatography afforded the 
phosphorylated derivatives 56a-d in good yields of up to 86% (Table 8).  
 
Table 8. Yields of phosphorylated products 56a-d. 
 
                                            
O
N
O
P
O
O
O
OR
1'
3'
1
2
3
4
1''
2''
                         
 
    Compound                            R                                           Yields/ % 
________________________________________________________________________ 
 
     56a                                          H                                                    60 
     56b                                     8-OCH2CH3                                                  77       
     56c                                      6-Cl                                                    77  
     56d                                     6-Br                                                    86 
________________________________________________________________________ 
 
The compounds were characterised using NMR and IR spectroscopy.  The 1H NMR 
spectra (e.g. Figure 18) of the phosphorylated derivatives 56 show additional signals, 
which are attributed to hindered rotation about the amide C-N bond. 1H NMR and 13C 
NMR spectra are illustrated in Figures 18a and 18b, respectively. The 1H NMR spectrum 
of compound 56d shows doublet at ca. 3.08 ppm corresponding to the methylene group 
attached directly to phosphorous, while the 1’-methylene protons resonate at 4.48 ppm 
and the 3’- methylene protons at 4.82 ppm. The 13C NMR spectrum of compound 56d 
reveals signals for the methylene carbons attached directly to phosphorus at 32.9 and 34.2 
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ppm, while the 1’- and 3’-methylene carbons resonate at 45.9 and 52.8 ppm, respectively. 
The DEPT 135 spectrum of compound 56d (Figure 18c) confirms the methylene carbons 
as negative signals. The coupling between methyl and methylene protons of the two 
ethoxy groups in compound 56d was evident from their COSY spectra, while the HSQC 
and HMBC spectra of these compounds show the correlations between protons and 
carbons (Figure 18d-f).   
 
ppm (f1) 1.02.03.04.05.06.07.08.09.0
7.
90
7
7.
65
1
7.
64
8
7.
55
9
7.
55
6
7.
54
4
7.
54
1
7.
36
6
7.
35
3
7.
34
1
7.
29
8
7.
28
6
7.
27
2
7.
25
0
7.
21
2
7.
19
9
7.
17
5
7.
16
1
4.
81
5
4.
48
8
4.
18
8
4.
17
6
4.
16
3
4.
15
1
4.
13
9
3.
12
3
3.
08
7
1.
32
3
1.
31
1
1.
29
9
0
.99
0
.97
1
.64
8
.71
1
.97
0
.62
0
.63
1
.94
5
.27
1
.40
10
.14
2
.00
O O
Br
N
O
P
O
O
O
 
Figure 18a. 400MHz 1H NMR spectrum of compound 56d in CDCl3. 
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Figure 18b. 100MHz 13C NMR spectrum of compound 56d in CDCl3. 
 
ppm (t1) 050100150
13
8.
03
7
13
3.
93
5
13
0.
22
2
12
9.
12
1
12
7.
97
1
12
6.
23
4
11
8.
09
5
62
.
94
4
62
.
87
9
52
.
81
3
48
.
80
0
45
.
89
0
34
.
21
7
32
.
91
8
16
.
33
9
16
.
27
6
400MHz,CDCl3, DEPT135, RJ500d
O
N
O
O
P
O
OO
Br
 
Figure 18c. DEPT135 spectrum of compound 56d in CDCl3. 
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Figure 18d. 400MHz COSY spectrum of compound 56d in CDCl3. 
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Figure 18e. HSQC spectrum of compound 56d in CDCl3. 
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Figure 18f. HMBC spectrum of compound 56d in CDCl3. 
 
2.4. Molecular modelling studies of phosphorylated derivatives  
 
Each of the phosphorylated derivatives was modelled as the corresponding hydrolysed 
analogues by replacing the ethoxy groups by hydroxyl groups. The assumption is that 
esters would be hydrolysed in vivo. Docking of these analogues into the HIV receptor 
cavity was explored using the Ligandfit module in the Accelrys Cerius2
 
platform on an 
SG-O2 computer, and potential hydrogen-bonding interactions between the enzyme and 
these ligands were indentified (Scheme 19). An HIV-1 protease X-ray diffraction 
structure containing ritonavir was used in the molecular modelling studies, and was 
downloaded from the Cambridge Crystallographic protein data bank (Figure 19).86 After 
removing ritonavir from the enzyme structure, the energy-minimised, phosphorylated 
derivatives were docked into the active site using the Cerius2 Ligandfit module. 
Application of the Ligandfit module involves a 4-step process, consisting of “Site 
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search”, “Conformation search”, “Ligand fitting” and “Ligand scoring”.87 The best-fit 
conformers were examined for their possible hydrogen-bonding interactions with the 
enzyme receptor and/or structural water molecules, and their docking scores, van der 
Waals and ligand scores are shown in Table 9. The hydrogen-bonding interactions 
between the enzyme receptor in the presence of structural water molecules and ligand 
56d are shown in Figures 20 and 21. Possible hydrogen-bonding interactions are 
indicated between: - i) a phosphoryl oxygen and two water molecules; ii) a water 
molecule and the amide nitrogen; iii) the carbonyl oxygen and a water molecule; and iv) 
the hydrogen of a hydroxyl group attached to phosphorous with the oxygen of a water 
molecule. Potential hydrogen-bonding interactions in the case of ligand 48d are 
illustrated in Figures 22 and 23. Such interactions are indicated between: - i) a water 
molecule and the bromine; ii) a water molecule and the coumarin ring oxygen; and iii) an 
Ile-50 (A) amide hydrogen with a hydroxyl oxygen attached to phosphorous. Possible 
hydrogen-bonding interactions between the ligand 49d and the enzyme receptor are 
shown in Figures 24 and 25. These involve interactions between: - i) the Gly-49 (A) 
residue and a hydrogen of a hydroxyl group attached to phosphorous; ii) Gly-48 (B) with 
the hydrogen of a hydroxyl group attached to phosphorous; and iii) a structural water 
molecule and the oxygen of the coumarin ring. 
               
O O
P
OHOH
O
R
48a-d
             
O O
P
O
OH
OH
R
49a-d
       
 
       
O O
N
O
P
O
OH
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6-Cl
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Scheme 19. Representative phosphorylated derivatives selected for docking in the HIV-1 
protease active site. 
                                                                                                                            Discussion                              
65 | P a g e  
 
 
Table 9. Docking scores, Ligandscores and van der Waals energies for selected ligands 
in the HIV-1 protease active site.  
________________________________________________________________________  
Ligands                           Docking score/         Ligand score/                 van der Waals/ 
                                             kcal.mol-1                kcal/mol-1                   energy/kcal.mol-1 
________________________________________________________________________ 
56a-OH                             33.421627                   2.95                    -29.79 
56b-OH                             35.307972                   0.85                                          -7.09  
56c-OH                             17.006662                    1.80                                       -24.27 
56d-OH                             11.487108                   2.27                                           5.17 
49a-OH                             11.223932                   1.44                    -14.13 
49b-OH                             31.294571                   1.13                       -10.76 
49c-OH           11.433449                  1.23           -4.30 
49d-OH                             15.306229                   1.39                                         -24.89 
48a-OH                             2.190857                    -0.83                                          25.73 
48b-OH                             26.244118                   1.36                                         -22.61     
48c-OH                               5.299529                  -0.29                                            2.54 
48d-OH                               9.531050                   1.42                                          -1.49    
________________________________________________________________________ 
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Figure 19. Ribbon representation of the X-ray crystal structure of HIV-1 protease 
showing ritonavir in the binding cavity as reported by Kempf et al.86 
 
 
The phosphorylated analogues 48a-d, 49a-d and 56a-d clearly have the ability to fit 
within the HIV-1 protease enzyme receptor cavity, and the potential to bind through the 
hydrogen-bonding interactions with structural water molecules and receptors subsites, 
such as Gly-48, Gly-49 and Ile-50. The next step in this research programme is expected 
to involve enzyme-inhibition and binding studies of the hydrolysed compounds. 
Active site 
Ritonavir 
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Figure 20: The best-fit conformation of ligand 56d-OH docked in the active site of HIV-
1 PR. The hydrogen-bonding interactions are represented by yellow dashed lines and 
reflect separations of less than 3.5Å. 
 
                             
                             
 
 
 
 
 
 
 
 
 
 
Figure 21: A simplified schematic diagram of ligand 56d-OH and structural water 
molecules in the active site of the HIV-1 PR enzyme showing potential hydrogen-
bonding interactions. 
Asp-25 
ASP-29 
Ile-50 
Water 
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Figure 22: The best-fit conformation of ligand 48d-OH docked in the active site of HIV-
1 PR. The hydrogen-bonding interactions are represented by yellow dashed lines and 
reflect separations of less than 3.5Å. 
 
                                           
 
 
 
 
 
 
 
 
 
 
Figure 23: A simplified schematic diagram of potential hydrogen-bonding interactions 
between ligand 48d-OH, the active site of HIV-1 PR enzyme and a structural water 
molecule.                                          
Ile-50 
Asp-25 
Asp-25’ 
water 
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Figure 24: The best-fit conformation of ligand 49d-OH docked in the active site of HIV-
1 PR. The hydrogen-bonding interactions are represented by green dashed lines and 
reflect separations of less than 3.5Å. 
 
 
                 
 
 
 
 
 
 
 
 
Figure 25: A simplified schematic diagram showing potential hydrogen-bond 
interactions between ligand 49d-OH, the active site of HIV-1 PR and a structural water 
molecule.                                          
 
 
 
 Gly-49 
 
Gly-48 
Water 
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2.5. Conclusions  
 
The cyclisation of unprotected Baylis-Hillman adducts have successfully afforded a 
series of the 3-(halomethyl)coumarin derivatives directly, without protecting the 
salicylaldehyde phenolic hydroxyl group. However, treatment of the halogen-substituted, 
unprotected Baylis-Hillman adducts with HI afforded the 6-halogeno-3-
(iodomethyl)coumarin derivatives and the unexpected 3-methyl analogues, the product 
distribution depending on the reaction times.  The application of the Arbuzov reaction to 
the 3-(halomethyl)coumarin derivatives has afforded both the 1’-phosphorylated 
derivatives and the unexpected 4-phosphorylated analogues. The regioselectivity of 
phosphorylation appears to depend on the nature of the leaving group (Cl or I) and the 
reaction conditions. Nucleophilic attack on the 3-(chloromethyl)coumarins by 
benzylamine gave the 3-[(benzylamino)methyl]coumarin derivatives, while treatment of 
these products with chloroacetyl chloride  afforded the corresponding chloroacetamides 
as mixtures of rotamers arising from hindered rotation about the C(O)-N amide bond. At 
high temperature (ca. 100oC) the relevant 1H NMR signals at 4.39 and 4.63 ppm were 
broadened and coalesced because the rate of internal rotation had increased. Modelling 
studies of hydrolysed analogues of the phosphorylated compounds have indicated their 
capacity to interact with the active site of the HIV-1 protease enzyme through hydrogen 
bonding with the structural water molecules and/or receptor subsites.  
 
The various objectives of the present study have been successfully achieved and future 
work based in this area of research is expected to include the following. 
 
1. Preparation of the 4-hydroxylated-3-(halomethyl)coumarin derivatives by 
oxidizing the Baylis-Hillman adducts prior to cyclisation. 
2. X-ray crystallographic analyses of the N-benzyl-2-chloro-N-[(2-oxo-2H-chromen-
3-yl)methyl]acetamides and their phosphorylated derivatives to establish solid-
state conformational preferences. 
                                                                                                                            Discussion                              
71 | P a g e  
 
3. Variable temperature NMR studies of internal rotation in the acetamide 
derivatives in DMSO-d6 at different temperatures to explore the rotational 
barriers. 
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3. EXPERIMETAL  
 
3.1. General 
 
NMR spectra were recorded on Bruker AMX 400 and Biospin 600 spectrometers at 303K 
in DMSO-d6 or CDCl3 and calibrated using solvent signals [7.25 (CHCl3) and 2.50 ppm 
(DMSO-d6) for 1H NMR; 77.0 (CDCl3) and 34.5 (DMSO-d6) for 13C NMR]. 31P NMR 
spectra were taken using phosphoric acid (H3PO4) as an internal reference. Melting points 
were measured using a Kofler hot stage apparatus and are uncorrected. Flash column 
chromatography was performed using Merck Silica gel 60 [particle size 0.040-0.063 mm 
(230-400 mesh)] and MN Kieselgel 60 (particle size 0.063-0.200 mm) and TLC was run 
on pre-coated Merck silica gel F254 plates viewed under UV light (254/365 nm) or 
following exposure to iodine vapour. Infrared spectra were obtained on a Perkin Elmer 
FT-IR Spectrum 2000 spectrometer using nujol mulls. Low-resolution (EI) mass spectra 
were obtained on a Finnigan-Mat GCQ mass spectrometer and high-resolution (EI) mass 
spectra on a VG70-SEQ Micromass double-focussing magnetic sector spectrometer 
(Potchefstroom University Mass Spectrometry Unit).  
 
The reagents used in the present study were supplied by Aldrich, and used without further 
purification. Solvents were distilled under nitrogen and stored over type 3A molecular 
sieves following methodology described by Perrin and Armarego.88 THF was distilled 
from sodium using benzophenone as indicator, and acetone was distilled from 3A 
molecular sieves. 
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3.2. Synthetic procedures 
 
3.2.1. Preparation of the salicylaldehyde benzyl ethers  
 
                                          
                               
O
H
O
 
                          2-Benzyloxybenzaldehyde 39a60 
 
To a mixture of salicylaldehyde (2.5g, 21mmol), benzyl bromide (2.5ml, 21mmol), 
anhydrous K2CO3 (16.9g, 0.12mol) and NaI (18.5g, 0.12mol) was added distilled acetone 
(40ml), and the mixture was boiled under reflux for 12h. Water (20ml) was then added 
and the organic aqueous layer extracted with CHCl3 (2 x 100ml). The combined organic 
extracts were then washed with brine and dried (anhydrous Na2SO4), filtered and 
concentrated in vacuo to give a dark brown oil. Separation using flash column 
chromatography [on silica gel; elution with ethyl acetate-hexane (1:9)] afforded 2-
benzyloxybenzaldehyde 39a as yellow crystals (1.2g, 27%); m.p. 43-46oC (lit.60 42-
44oC); ν
max 
(nujol)/cm-1 1697 (C=O); δH (400 MHz; CDCl3) 5.18 (2H, s, CH2), 7.02-7.45 
(7H, series of multiplets, Ar-H), 7.51 (1H, t, J = 7.2Hz, Ar-H), 7.85 (1H, d, J = 7.6Hz, 
Ar-H) and 10.57 (1H, s, CHO); δC (100 MHz; CDCl3) 70.4 (CH2), 113.0, 120.9, 125.1, 
127.2, 128.2, 128.3, 128.6, 135.8, 136.0 and 161.0 (Ar-C) and 189.6 (C=O). 
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O
H
O
O
 
                               2-Benzyloxy-3-ethoxybenzaldehyde 39b 60 
 
The procedure described for the synthesis of 2-benzyloxybenzaldehyde 39a was 
followed, using 3-ethoxysalicylaldehyde (2.0g, 7mmol), benzyl bromide (2.0ml, 17 
mmol), anhydrous K2CO3 (10.4g, 73mmol) and NaI (11.3g, 73mmol) in distilled acetone 
(80ml). Work-up and chromatography afforded 2-benzyloxy-3-ethoxybenzaldehyde 39b 
as a pale orange crystals (1.89g, 42%); m.p. 36-39oC (lit.60 36-38oC
 
); ν
max 
(nujol)/cm-1 
1693 (C=O); δH  (400 MHz; CDCl3) 1.49 (3H, t, J =7.0Hz, CH2CH3), 4.11 (2H, q, J = 
7.1Hz, OCH2CH3), 5.19 (2H, s, CH2Ph), 7.10-7.41 (8H, series of overlapping signals, Ar-
H) and 10.26 (1H, s, CHO); δC (100 MHz; CDCl3) 14.8 (CH3), 64.6 (CH2), 76.2 (CH2Ph), 
118.9, 119.1, 124.1, 128.4, 128.5, 128.6, 130.3, 136.5, 151.2 and 152.3 (Ar-C) and 190.2 
(C=O). 
 
                                                
H
O
O
OMe
 
                                 2-Benzyloxy-3-methoxybenzaldehyde 39c 60 
 
The procedure described for the synthesis of 2-benzyloxybenzaldehyde 39a was 
followed, using 3-methoxysalicylaldehyde (1.19g, 8mmol), benzyl bromide (1ml, 
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8mmol), anhydrous K2CO3 (6.5g, 0.03mol) and NaI (7.1g, 0.03mmol) in distilled acetone 
(40ml). Work-up and chromatography afforded 2-benzyloxy-3-methoxybenzaldehyde 
39c as a pale yellow crystals (1.01g, 54%); m.p. 37-40oC (lit.60 36-38oC
 
); ν
max 
(nujol)/cm-1 1688 (C=O); δH  (400 MHz; CDCl3) 3.93 (3H, s, OCH3), 5.17 (2H, s, 
CH2Ph), 7.12 (2H, series of overlapping multiplets, Ar-H), 7.34 (6H, series of 
overlapping signals, Ar-H) and 10.3 (1H, s, CHO); δC (100 MHz; CDCl3) 56.1 (OCH3), 
76.3 (CH2Ph), 118.0, 119.0, 124.2, 128.5, 128.6, 130.3, 130.8, 136.4, 151.0 and 153.0 
(Ar-C) and 190.2 (C=O). 
 
3.2.2. Preparation of O-benzylated Baylis-Hillman adducts 
                               
OH
O
O
O
 
             Methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 40a 60 
 
A mixture of 2-benzyloxybenzaldehyde 39a (1.0g, 5.0mmol), methyl acrylate (2.4ml, 
5mmol) and DABCO (0.91g, 3mmol) in CHCl3 (1.25ml) was stirred in a stoppered 
reaction flask for three weeks. The mixture was concentrated in vacuo to give a brown 
oil, which was purified by flash column chromatography [on silica gel; elution with 
hexane-EtOAc (9:1)] to afford methyl 3-(-2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanoate 40a as a pale yellow oil
 
(0.32g, 23%); ν
max 
(thin film)/cm-1 3508 
(OH) and 1725 (C=O); δH (400 MHz; CDCl3) 3.42 (1H, br s, OH), 3.71 (3H, s, OCH3), 
5.08 (2H, s, OCH2Ph), 5.69 and 6.28 (2H, 2 x s, C=CH2), 5.94 (1H, s, CH), 6.93-7.00 
(2H, overlapping multiplets, Ar-H), 7.22-7.41 (7H, series of overlapping multiplets, Ar-
H); δC (100 MHz; CDCl3) 51.8 (OCH3), 68.5 (CHOH), 70.2 (OCH2), 111.9, 121.0, 125.8, 
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127.3, 127.8, 128.0, 128.6, 128.8, 129.6, 136.7, 141.4 and 155.7 (C=CH2 and Ar-C) and 
167.0 (C=O). 
 
                                  
OH
O
O
O
O
 
  Methyl 3-(2-benzyloxy-3-ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 40b 60   
 
The procedure described for the synthesis of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanoate 40a was followed, using 2-benzyloxy-3-ethoxybenzaldehyde 39b 
(1.52g, 6mmol), methyl acrylate (1.2ml, 12mmol) and DABCO (1.25g, 3mmol) in CDCl3 
(1.25ml). Work up and chromatography afforded methyl 3-(2-benzyloxy-3-
ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 40b as a pale yellow oil (0.538g, 
27%); ν
max 
(thin film)/cm-1 3515 (OH) and 1719 (C=O); δH (400 MHz; CDCl3) 1.45 (3H, 
t, J = 7Hz, CH2CH3), 3.59 (1H, s, OH), 3.69 (3H, s, OCH3), 4.07 (2H, q, J = 7Hz, 
OCH2CH3), 5.09 (2H, s, OCH2Ph), 5.72 and 6.28 (2H, 2 x s, C=CH2) 5.87 (1H, s, 
CHOH) and 6.88-7.47 (8H, series of multiplets, Ar-H); δC (100 MHz; CDCl3) 15.0 
(OCH2CH3), 51.8 (OCH3), 64.3 (OCH2CH3), 67.9 (CHOH), 74.6 (OCH2Ph), 113.2, 
119.3, 124.1, 125.8, 128.0, 128.3, 128.4, 135.1, 137.7, 141.7, 145.4 and 151.8 (C=CH2 
and Ar-C) and 166.8 (C=O).  
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3.2.3. Cyclisation of O-benzylated Baylis-Hillman adducts  
 
                                              
O
Cl
O
 
                                3-(Chloromethyl)coumarin 41a60 
Conc. HCl (4ml) was added to a solution of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanoate 40a (0.531g, 2mmol) in AcOH (2ml). The mixture was boiled 
under reflux for 2h, allowed to cool to room temperature and then poured into ice-cooled 
water (20ml). Stirring for ca. 30min gave a precipitate, which was filtered off and washed 
with hexane to afford 3-(chloromethyl)coumarin 41a as a grey solid  (0.287g, 83%); m.p. 
108-110oC (lit.60 108-110oC); ν
max 
(nujol)/cm-1 1713 (C=O); δH (400 MHz; CDCl3) 4.54 
(2H, s, CH2Cl), 7.28-7.53 (4H, series of multiplets, Ar-H) and 7.87 (1H, s, 4-H); δC (100 
MHz; CDCl3) 41.0 (CH2), 116.6, 118.8, 124.70, 125.0; 128.0, 132.0, 141.1 and 153.45 
(Ar-C) and 160.1 (C=O).  
 
                                              
O
Cl
O
O
 
                             3-(Chloromethyl)-8-ethoxycoumarin 41b60 
 
The procedure described for the synthesis of 3-(chloromethyl)coumarin 41a was 
followed, using conc. HCl (4ml) and a solution of methyl 3-(2-benzyloxy-3-
ethoxyphenyl)-3-hydroxy-2-methylenepropanoate 40b  (1.21g, 4mmol) in AcOH (1ml) 
and Ac2O (1ml). Work-up afforded, as a pale pink solid, 3-(chloromethyl)-8-
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ethoxycoumarin 41b (0.59g, 70%); m.p. 121-124oC (lit.60 122-124oC); ν
max 
(nujol)/cm-1 
1709 (C=O); δH (400 MHz; CDCl3) 1.45 (3H, t, J = 7Hz, CH2CH3), 4.14 (2H, q, J = 7Hz, 
OCH2CH3), 4.52 (2H, s, CH2Cl), 7.04-7.07 (2H, m, Ar-H), 7.16 (1H, t, Ar-H) and 7.83 
(1H, s, 4-H); δC (100 MHz; CDCl3) 14.7 (CH2CH3), 41.0 (CH2Cl), 65.0 (OCH2CH3), 
115.2, 119.3, 119.5, 124.5, 125.1, 141.3, 143.4 and 146.5 (Ar-C) and 159.7 (C=O).    
                                          
O
I
O
 
                                 3-(Iodomethyl)coumarin 42a60 
 
Conc. HI (4ml) was added to a solution of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-
methylenepropanoate 40a (0.46g, 2mmol) in a mixture of AcOH (2ml). The mixture was 
boiled under reflux for 2h, allowed to cool to room temperature and then poured into ice-
cooled water (10ml). Stirring for ca. 30min gave a precipitate, which was filtered off and 
washed with hexane to afford 3-(iodomethyl)coumarin 42a as a grey solid (0.287g, 65%); 
m.p. 150-153oC (lit.60 150-152oC); ν
max 
(nujol)/cm-1 1710 (C=O); δH (400 MHz; CDCl3) 
4.37 (2H, s, CH2I), 7.28-7.53 (4H, series of overlapping multiplets, Ar-H) and 7.84 (1H, 
s, 4-H); δC (100 MHz; CDCl3) –1.5 (CH2I), 116.8, 119.1, 124.7, 127.2, 127.8, 131.9, 
140.3 and 153.5 (Ar -C) and 159.8 (C=O). 
                    
                                                  
O
I
O
O
 
                                      8-Ethoxy-3-(iodomethyl)coumarin 42b60 
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The procedure described for the synthesis of 3-(iodomethyl)coumarin 42a was followed, 
using conc. HI (4ml) and methyl 3-(2-benzyloxy-3-ethoxyphenyl)-3-hydroxy-2-
methylenepropanoate 40b  (0.312g, 1mmol) in a mixture of AcOH (5ml). Work-up 
afforded, as a pale yellow solid, 3-(iodomethyl)-8-ethoxycoumarin 42b (0.187g, 62%); 
m.p. 119-122oC (lit.60 120-122); ν
max 
(nujol)/cm-1 1718 (C=O); δH (400 MHz; CDCl3) 
1.47 (3H, t, J = 6.8Hz, CH2CH3), 4.14 (2H, q, J = 7Hz, OCH2CH3), 4.36 (2H, s, CH2I), 
7.01 (2H, overlapping multiplets, Ar-H), 7.15 (1H, t, J = 8Hz, Ar-H) and 7.79 (1H, s, 4-
H). δC (100 MHz; CDCl3) –1.5 (CH2I), 14.7 (CH2CH3), 65.1 (OCH2CH3), 115.1, 119.1, 
119.8, 124.5, 127.4, 140.7, 143.4 and 146.5 (Ar-C) and 159.4 (C=O). 
 
3.2.4. Synthesis of Baylis-Hillman products using tert-butyl acrylate.  
                                             
O
OOH
OH
 
        tert-Butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropanoate 24a60 
 
A mixture of salicylaldehyde (5.0ml, 41mmol), tert-butyl acrylate (10.5ml, 115mmol) 
and DABCO (4.3g, 39mmol) in CHCl3 (15ml) was stirred in a stoppered reaction flask 
for 14 days. The mixture was concentrated in vacuo to give a dark brown oil, which was 
purified using flash column chromatography [on silica gel; elution with hexane-EtOAc 
(9:1)] to afford tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-methylenepropanoate 24a as 
a pale yellow oil which later crystallized (2.56g, 25%); m.p.107-111oC (lit.60 108-110
o
C); 
ν
max 
(nujol)/cm-1: 3442 (OH) and 1728 (C=O); δH (400 MHz; CDCl3) 1.50 [9H, s, 
C(CH3)3], 4.35 (1H, s, OH), 5.50 and 6.23 (2H, 2x s, C=CH2), 5.69 (1H, s, CHOH), 6.81-
7.21 (4H, series of multiplets, Ar-H) and 8.12 (1H, s, ArOH); δC (100 MHz; CDCl3) 28.0 
[C(CH3)3], 73.6 (CHOH), 82.6 [C(CH3)3], 117.5, 119.8, 124.1, 124.2, 127.8, 129.5, 140.9 
and 155.9 (C=CH2 and Ar-C) and 166.7 (C=O). 
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OH
O
O
OH
O
 
        tert-Butyl 3-hydroxy-3-(3-ethoxy-2-hydroxyphenyl)-2-methylenepropanoate 24b60 
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-
2-methylenepropanoate 24b was followed, using 3-ethoxysalicylaldehyde (2.0g, 
12mmol), tert-butyl acrylate (2.5ml, 17mmol) and DABCO (0.86g, 7.7mmol) in CHCl3 
(3ml). Work-up and chromatography [on silica gel; elution with EtOAc-hexane (1:8)] 
afforded tert-butyl 3-hydroxy-3-(3-ethoxy-2-hydroxyphenyl)-2-methylenepropanoate 
24b as a pale yellow oil  (0.68g, 20%); ν
max 
/cm-1 3502 (OH) and 1714 (C=O); δH (400 
MHz; CDCl3) 1.41 [12H, overlapping s and t, C(CH3)3 and CH2CH3], 3.60 (1H, d, J = 
5.6Hz, OH), 4.07 (2H, q, J = 6.9Hz, OCH2CH3), 5.66 and 6.22 (2H, 2 x s, C=CH2), 5.81 
(1H, d, J = 5.2Hz, CHOH), 6.43 (1H, s, ArOH) and 6.78-6.84 (3H, series of overlapping 
signals, Ar-H); δC (100 MHz; CDCl3) 14.9 (CH2CH3), 28.0 [C(CH3)3], 64.6 (OCH2CH3), 
69.4 (CHOH), 81.6 [C(CH3)3], 111.4, 119.5, 119.6, 125.1, 126.6, 142.2, 143.7 and 146.1 
(C=CH2 and Ar-C) and 166.1 (C=O). 
  
 
                                             
OH
O
O
OH
Cl
 
 
   tert-Butyl 3-(5-chloro-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 24c60 
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The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-
2-methylenepropanoate 24a was followed, using 5-chlorosalicylaldehyde (7.02g, 
46mmol), tert-butyl acrylate (12ml, 95mmol) and DABCO (8.8g, 33mmol) in CHCl3 
(8ml) and stirring for 4 days. The reaction mixture was filtered through a layer of silica 
gel. Crystallization from CHCl3 afforded tert-butyl 3-(5-chloro-2-hydroxyphenyl)-3-
hydroxy-2-methylenepropanoate 24c as white crystals (7.25g, 56%); m.p. 185-187oC 
(lit.60 186-188); ν
max 
(nujol)/cm-1
 
3309 (OH) and 1686 (C=O); δH (400 MHz; DMSO-d6) 
1.32 [9H, s, C(CH3)3], 5.52 (1H, s, CHOH), 5.64 and 6.06 (2H, 2 x s, C=CH2), 5.67 (1H, 
CHOH), 6.78 (1H, d, J = 8.4Hz, Ar-H), 7.05-7.11 (2H, multiplets, Ar-H) and 9.71 (1H, s, 
ArOH); δC (100 MHz; DMSO-d6) 27.5 [C(CH3)3], 64.5 (CHOH), 80.1 [C(CH3)3], 116.5, 
122.0, 123.0, 126.9, 127.5, 131,3 144.8 and 153.3 (C=CH2 and Ar-C) and 165.0 (C=O). 
 
                                         
OH
O
O
OH
Br
 
    tert-Butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 24d60  
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-
2-methylenepropanoate 24a was followed, using 5-bromosalicylaldehyde (2g, 10mmol), 
tert-butyl acrylate (2.1ml, 15mmol) and DABCO (0.86g, 7.7mmol) in CHCl3 (3ml) and 
stirring for 4 days. The reaction mixture was filtered through a layer of silica gel. 
Crystallization from CHCl3 afforded tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-
2-methylenepropanoate 24d as white crystals (1.75g, 53%); m.p. 185-187oC (lit.60 186-
188oC); ν
max 
(nujol)/cm-1
 
3304 (OH) and 1688 (C=O); δH (400 MHz; DMSO-d6) 1.32 
[9H, s, C(CH3)3], 5.48 (1H, br s, OH), 5.65 and 6.05 (2H, 2 x s, C=CH2), 5.66 (1H, s, 
CHOH), 6.74 (1H, d, J = 8.4Hz, Ar-H), 7.19 -7.22 (2H, m, Ar-H) and 9.70 (1H, br, 
ArOH); δC (100 MHz; DMSO-d6) 27.4 [C(CH3)3], 64.5 (CHOH), 80.0 [C(CH3)3], 109.6, 
117.1, 122.8, 129.7, 130.3, 131.8, 144.8 and 153.7 (C=CH2 and Ar-C) and 164.9 (C=O). 
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OH
O
O
OH
OMe
       
    tert-Butyl 3-hydroxy-3-(2-hydroxy-3-methoxyphenyl)-2-methylenepropanoate24e60 
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-
2-methylenepropanoate 24a was followed, using 3-methoxysalicylaldehyde (4.32g, 
28mmol), tert-butyl acrylate (7.3ml, 57mmol) and DABCO (2.58g, 23mmol) in CDCl3 
(12ml). Work-up and chromatography [on silica gel; elution with EtOAc-hexane (1:6)] 
afforded tert-butyl 3-hydroxy-3-(2-hydroxy-3-methoxy-phenyl)-2-methylenepropanoate 
24e as a brown-yellow oil (1.69g, 25%); ν
max 
/cm-1 3482 (OH) and 1717 (C=O); δH (400 
MHz; CDCl3) 1.43 [9H, C(CH3)3], 3.90 (1H, s, OH), 3.86 (3H, s, CH3) 5.65 and 6.21 
(2H, 2x s, C=CH2), 5.81 (1H, s, CHOH) and 6.80 (3H, series of overlapping signals, Ar-
H); δC (100 MHz, CDCl3):  27.8 [C(CH3)3], 55.9 (OCH3), 69.3 (CHOH), 81.4 [C(CH3)3], 
110.3, 119.3, 119.6, 124.8, 126.5, 142.2, 143.6 and 147.0 (C=CH2 and Ar-C) and 165.9 
(C=O). 
 
3.2.5. Cyclisation of Baylis-Hillman adducts 
 
3.2.5.1. Synthesis of 3-(iodomethyl)coumarin derivatives  
                                                
O
I
O
 
                                          3-(Iodomethyl)coumarin 42a60 
 
Conc. HI (10ml) was added to a solution of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-2-
methylenepropanoate 24a (0.50g, 2.0mmol) in a mixture of AcOH (5ml) and Ac2O (5ml). 
The mixture was boiled under reflux for 2h, allowed to cool to room temperature and 
then poured into ice-cooled water (10ml). Stirring for ca. 30min gave a precipitate, which 
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was filtered off and washed with hexane to afford 3-(iodomethyl)coumarin 42a as a grey 
solid (0.35g, 60%); m.p. 148-151oC (lit.61 150-152oC); ν
max 
(nujol)/cm-1 1710 (C=O); δH 
(400 MHz; CDCl3) 4.37 (2H, s, CH2I), 7.25-7.52 (4H, series of overlapping multiplets, 
Ar-H) and 7.83 (1H, s, 4-H); δC (100 MHz; CDCl3) -1.6 (CH2I), 116.8, 119.1, 124.7, 
127.2, 127.8, 131.9, 140.4 and 153.5 (Ar -C) and 159.8 (C=O). 
                  
 
                                                  
O
I
O
O
 
                                 8-Ethoxy-3-(iodomethyl)coumarin 42b60  
 
The procedure described for the synthesis of 3-(iodomethyl)coumarin 42a was followed, 
using conc. HI (10ml) and tert-butyl 3-ethoxy-3(-2-hydroxyphenyl)-3-hydroxy-2-
methylenepropanoate 24b (0.58g, 2mmol) in a mixture of AcOH (5ml) and Ac2O (5ml). 
Work-up afforded, as a pale yellow solid, 3-(iodomethyl)-8-methoxycoumarin 42b 
(0.29g, 62%); m.p. 120-123oC (lit.60 120-122oC); ν
max 
(nujol)/cm-1 1718 (C=O); δH (400 
MHz; CDCl3) 1.46 (3H, t, J = 6.8Hz, CH2CH3), 4.14 (2H, q, J = 7Hz, OCH2CH3), 4.36 
(2H, s, CH2I), 7.01-7.07 (2H, overlapping multiplets, Ar-H), 7.15 (1H, t, Ar-H) and 7.80 
(1H, s, 4-H); δC (100 MHz; CDCl3) -1.5 (CH2I), 14.7 (CH2CH3), 65.1 (OCH2CH3), 115.1, 
119.1, 119.9, 124.6, 127.4, 140.7, 143.4 and 146.6  (Ar-C) and 159.4 (C=O). 
 
3.2.5.2. Optimisation Studies of reactions of compound 24c and d with HI. 
 
             
O
I
O
Br
                            
O O
Br
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         6-Bromo-3-(iodomethyl)coumarin 42d
 
60
       6-Bromo-3-methylcoumarin 47d 
                                                    
Conc. HI (10ml) was added to a solution of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-
hydroxy-2-methylenepropanoate 24d (0.61g, 1.0mmol) in a mixture of AcOH (5ml) and 
Ac2O (5ml). The mixture was boiled under reflux for 2h, allowed to cool to room 
temperature and then poured into ice-cooled water (10ml). Stirring for ca. 30min gave a 
precipitate, which was filtered off and washed with hexane. The products were separated 
by flash column chromatography [on silica gel; elution with ethyl acetate-hexane (1:5)] to 
afford two fractions. 
 
Fraction 1: 6-Bromo-3-(iodomethyl)coumarin 42d as a grey solid (0.349g, 52%); m.p. 
147-149oC (lit.60 148-150oC); ν
max 
(nujol)/cm-1 1722 (C=O); δH (400 MHz; CDCl3) 4.40 
(2H, s, CH2I), 7.27 (1H, s, Ar-H); 7.47-7.66 (2H, series of overlapping signals, Ar-H) and 
7.80 (1H, s, 4-H); δC (100 MHz; CDCl3) –2.2 (CH2I), 117.3, 118.5, 120.6, 128.6, 130.0, 
134.5, 139.9 and 152.3 (Ar-C) and 159.1 (C=O). 
 
 Faction 2: 6-Bromo-3-methylcoumarin 47d as a grey solid (0.189g, 43%); m.p. 154-
156oC; ν
max 
(nujol)/cm-1 1729 (C=O); δH (400 MHz; CDCl3) 2.21 (3H, s, CH3), 7.17 (1H, 
m, Ar-H), 7.53 (2H, s, Ar-H) and 7.51 (1H, s, 4-H); δC (100 MHz; CDCl3) 17.3 (CH3), 
116.8, 118.2, 121.1, 127.2, 129.2, 133.2, 137.8 and 152.0 (Ar-C) and 161.5 (C=O).  
 
 
               
O
Cl
O
I
                                   
O
Cl
O
 
 6-Chloro-3-(Iodomethyl)coumarin 42c
 
60
       6-Chloro-3-methylcoumarin 47c 
 
The procedure described for the synthesis of 6-bromo-3-(iodomethyl)coumarin 42d and 
6-bromo-3-methyl-2H-chromen-2-one 47d was followed, using conc. HI (10ml) and tert-
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butyl 3-(5-chloro-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 24c (0.52g, 
2mmol) in a mixture of AcOH (5ml) and Ac2O (5ml). Work-up and chromatography [on 
silica gel; elution with ethyl acetate-chloroform-hexane (1:1:3) afforded two fractions. 
 
Fraction 1: 6-Chloro-3-(iodomethyl)coumarin 42c as a yellow solid (0.308g, 52%); 186-
189oC (lit.60 188-190); νmax (nujol)/cm-1 1723 (C=O); (400 MHz; CDCl3) 4.35 (2H, s, 
CH2I), 7.28 (1H, s, Ar-H) 7.45 (2H, series of overlapping signals, Ar-H) and 7.75 (1H, s, 
4-H); δC  (100 MHz; CDCl3) -2.2 (CH2I), 118.2, 120.1, 126.1, 128.5, 130.0, 131.7, 139.0 
and 151.8 (Ar-C) and 159.2 (C=O). 
  
Fraction 2: 6-Chloro-3-methylcoumarin 47c as pale yellow solid (0.162g, 45%); m.p 
1128-132oC (lit.60 158-160); ν
max 
(nujol)/cm-1 1731 (C=O); δH  (400 MHz; CDCl3) 2.21 
(3H, s, CH3), 7.26 and 7.42 (3H, m, Ar-H), and 7.40 (1H, s, 4-H); δC (100 MHz; CDCl3) 
17.3 (CH3), 117.9, 120.5, 126.2, 127.2, 129.4, 130.4, 137.9 and 151.6 (Ar-C) and 161.5 
(C=O).  
 
                                                 
O
I
O
Br
   
                                6-Bromo-3-(iodomethyl)coumarin 42d60 
     
Conc. HI (10ml) was added to a solution tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-
hydroxy-2-methylenepropanoate 24d (0.51g, 2mmol) in a mixture of AcOH (5ml) and 
Ac2O (5ml). The mixture was boiled under reflux for 1h, allowed to cool to room 
temperature and then poured into ice-cooled water (10ml). Stirring for ca. 30min gave a 
precipitate, which was filtered off and washed with hexane 6-bromo-3-
(iodomethyl)coumarin 42d a grey solid (0.33g, 58%). 
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O
I
O
Cl
 
                                        6-Chloro-3-(iodomethyl)coumarin 42c60 
 
The procedure described for the synthesis of 6-bromo-3-(iodomethyl)coumarin 42d was 
followed, using conc. HI (10ml) and tert-butyl 3-(5-chloro-2-hydroxyphenyl)-3-hydroxy-
2-methylenepropanoate 24c  (0.37g, 1.0mmol) in a mixture of AcOH (5ml) and Ac2O 
(5ml). Work-up and afforded 6-chloro-3-(iodomethyl)coumarin 42c as a grey solid 
(0.23g, 61%).  
                                                  
O O
Cl
 
                                                        6-Chloro-3-methylcoumarin 47c 
 
 
Conc. HI (10ml) was added to a solution of tert-butyl 3-hydroxy-3-(5-chloro-2-
hydroxyphenyl)-2-methylenepropanoate 24a (0.38g, 1mmol) in a mixture of AcOH (5ml) 
and Ac2O (5ml). The mixture was boiled under reflux for 8h, allowed to cool to room 
temperature and then poured into ice-cooled water (10ml). Stirring for ca. 30min gave a 
precipitate, which was filtered off and washed with hexane to afford, as a pale yellow 
solid, 6-chloro-3-methylcoumarin 47c (0.237g, 91%). 
 
                                                       
O O
Br
 
                                       6-Bromo-3-methylcoumarin 47d 
 
The procedure described for the synthesis of 6-chloro-3-methylcoumarim 47c was 
followed, using conc. HI (10ml) and a solution of tert-butyl 3-(5-bromo-2-
hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 24d (0.41g, 2mmol) in AcOH (5ml) 
and AcOH (5ml). Work-up afforded 6-bromo-3-methylcoumarin 47d as a grey solid 
(0.298g, 80%). 
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3.2.5.3. Synthesis of 3-(chloromethyl)coumarin derivatives  
 
                                              
O
Cl
O
 
                                    6-(Chloromethyl)coumarin 41c60 
Conc. HCl (10ml) was added to a solution of tert-butyl 3-hydroxy-3-(2-hydroxyphenyl)-
2-methylenepropanoate 24a (2.02g, 81mmol) in AcOH (10ml). The mixture was boiled 
under reflux for 2h, allowed to cool to room temperature and then poured into ice-cooled 
water (20ml). Stirring for ca. 30min gave a precipitate, which was filtered off and washed 
with hexane to afford 3-(chloromethyl)coumarin 41a as a grey solid  (1.02g, 65%); m.p. 
108-110oC (lit.60 108-110oC); ν
max 
(nujol)/cm-1 1713 (C=O); δH (400 MHz; CDCl3) 4.53 
(2H, s, CH2Cl), 7.27-7.55 (4H, series of multiplets, Ar-H) and 7.87 (1H, s, 4-H); δC (100 
MHz; CDCl3) 41.0 (CH2), 116.6, 118.7, 124.7, 124.9; 128.0, 132.0, 141.1 and 153.5 (Ar-
C) and 160.0 (C=O). 
                                              
O
Cl
O
O
 
                             3-(Chloromethyl)-8-ethoxycoumarin 41b60 
 
The procedure described for the synthesis of 3-(chloromethyl)coumarin 41a was 
followed, using conc. HCl (10ml) and a solution of tert-butyl 3-(8-ethoxy-2-
hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 24b (0.55g, 2mmol) in AcOH (5ml). 
Work-up afforded, as a pale pink solid, 3-(chloromethyl)-8-ethoxycoumarin 41 (0.299g, 
74%); m.p. 122-125oC (lit.60 122-124oC); ν
max 
(nujol)/cm-1 1709 (C=O); δH (400 MHz; 
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CDCl3) 1.46 (3H, t, J = 7Hz, CH2CH3), 4.14 (2H, q, J = 7Hz, OCH2CH3), 4.53 (2H, s, 
CH2Cl), 7.05-7.07 (2H, m, Ar-H), 7.17 (1H, t, J = 8Hz Ar-H) and 7.83 (1H, s, 4-H); δC 
(100 MHz; CDCl3) 14.7 (CH2CH3), 41.0 (CH2Cl), 65.0 (OCH2CH3), 115.2, 119.3, 119.5, 
124.5, 125.1, 141.3, 143.4 and 146.5 (Ar-C) and 159.7 (C=O).    
 
                                                
O
Cl
Cl
O
 
                            6-Chloro-3-(chloromethyl)coumarin 41c60 
 
The procedure described for the synthesis of 3-(chloromethyl)coumarin 41a was 
followed, using conc. HCl (10ml) and a solution of tert-butyl 3-(5-chloro-2-
hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 24d (2.32g, 8mmol) in AcOH (8ml) 
Work-up afforded 6-chloro-3-(chloromethyl)coumarin 41c as a pale pink solid (1.50g, 
80%); m.p. 110-114oC (lit.60 112-114oC); ν
max 
(nujol)/cm-1 1722 (C=O); δH (400 MHz; 
CDCl3) 4.52 (2H, s, CH2Cl), 7.27 (1H, s, Ar-H), 7.45-7.48 (2H, overlapping multiplets, 
Ar-H) and 7.80 (1H, s, 4-H); δC (100 MHz; CDCl3) 40.8 (CH2), 118.0, 119.7, 126.2, 
127.2, 129.9, 131.8, 139.7, and 151.7 (Ar-C ) and  159.4 (C=O).  
 
                                             
O
Cl
O
Br
 
                                   6-Bromo-3-(chloromethyl)coumarin 41d60 
 
The procedure described for the synthesis of 3-(chloromethyl)coumarin 41a was 
followed, using conc. HCl (10ml) and a solution of tert-butyl 3-(5-bromo-2-
hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 24d (1.52g, 1.0mmol) in AcOH 
(6ml) Work-up afforded 6-bromo-3-(chloromethyl)coumarin 41d as a pale pink solid 
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(1.21g, 95%); m.p. 113-115oC (lit.60 112-114 oC); ν
max 
(nujol)/cm-1
 
1722 (C=O); δH (400 
MHz; CDCl3) 4.53 (2H, s, CH2Cl), 7.21 (1H, d, Ar-H), 7.61-7.65 (2H, m, Ar-H) and 7.80 
(1H, s, 4-H); δC  (100 MHz; CDCl3) 40.7 (CH2), 117.2, 118.3, 120.24, 126.2, 130.2, 
134.6, 139.5, and 152.3 (Ar-C ) and  159.3 (C=O). 
 
                                                
O O
Cl
O
   
                                3-(Chloromethyl)-8-methoxycoumarin 41e60  
 
The procedure described for the synthesis of 3-(chloromethyl)coumarin 41a was 
followed, using conc. HCl (10ml) and a solution of tert-butyl 3-(8-methoxy-2-
hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 24e (1.02g, 4mmol) in AcOH (8ml). 
Work-up afforded 3-(chloromethyl)-8-methoxycoumarin 41e as a pale grey solid (0.54g, 
65%); m.p. 144-148oC (lit.60 146-148oC); ν 
max 
(nujol)/cm-1 1709 (C=O); δH (400 MHz; 
CDCl3) 3.94 (3H, s, OCH3), 4.53 (2H, s, CH2Cl), 7.06 (2H, d, J = 8 Hz, Ar-H), 7.19 (1H, 
t, J = 8 Hz, Ar-H) and 7.84 (1H, s, 4-H); δC (100 MHz; CDCl3) 40.9 (OCH3), 56.2 
(CH2Cl), 113.8, 119.3, 124.5, 125.1, 141.2, 143.1 and 147.0 (Ar-C) and 159.5 (C=O). 
 
3.2.6. Synthesis of benzylamine derivative from 3-(chloromethyl)coumarin 
derivatives. 
 
                                                  
O O
N
H
 
                                             3-(Benzylaminomethyl)coumarin 53a54  
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A mixture of 3-(chloromethyl)coumarin 42a (0.31g, 1.2mmol) and benzylamine (0.34ml) 
in THF (6ml) was stirred in a stoppered reaction flask for 4 hours. The mixture was 
concentrated in vacuo and separated by flash chromatography [on silica gel; elution with 
CHCl3-EtOAc (4:1)] to afford 3-(benzylaminomethyl)coumarin 53a as a pale yellow 
solid (0.31g, 74%); m.p. 70-74oC (lit.54 70-74oC); ν
 max 
(nujol)/cm-1 
 
3324 (N-H) and 1720 
(C=O); δH (400 MHz; CDCl3) 1.99 (1H, br s, NH), 3.74 (2H, s, 1’-CH2), 3.84 (2H, s, 
CH2Ph), 7.23-7.36 (7H, series of overlapping signals, Ar-H), 7.44-7.50 (2H, m, Ar-H,) 
and 7.71 (1H, s, 4-H);
 
δC (100 MHz; CDCl3) 48.4 and 53.2 (2xCH2), 116.4, 119.2, 124.4, 
127.1, 127.4, 127.5, 128.1, 128.4, 130.9, 139.2, 139.7 and 153.1 (Ar-C) and 161.4 (C=O). 
                                     
O O
N
H
O
 
                          3-(Benzylaminomethyl)-8-ethoxycoumarin 53c54 
 
The procedure described for the synthesis of 3-(benzylaminomethyl)coumarin 53a was 
followed, using 8-ethoxy-3-(chloromethyl)coumarin 42b (0.2g, 9mmol) and benzylamine 
(0.15ml) in THF (4ml). Work-up and chromatography [on silica gel, elution with CHCl3-
EtOAc 4:1)] afforded 3-(benzylaminomethyl)-8-ethoxycoumarin 53b as a pale yellow 
solid (0.19g, 73%); m.p. 97-101oC (lit.54 98-102); ν
max
(nujol)/cm-1 3425 (NH) and 1714 
(C=O); δH (400 MHz; CDCl3) 1.47 (3H, t, J = 7 \Hz, CH2CH3), 2.10 (1H, br s, NH), 3.75 
(2H, s, 1’-CH2), 3.83 (2H, s, CH2Ph), 4.15 (2H, q, J = 6.8 \Hz, OCH2CH3), 7.01-7.36 
(8H, series of multiplets, Ar-H) and 7.68 (1H, s, 4-H); δC (100 MHz; CDCl3) 14.7 
(CH2CH3), 48.4 and 53.1 (2xCH2N), 65.0 (OCH2CH3), 114.3, 119.0, 120.0, 124.2, 127.1, 
127.4, 128.1, 128.4, 139.5, 139.7, 143.1 and 146.4 (Ar-C) and 161.1 (C=O). 
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O O
N
H
Cl
 
                            3-(Benzylaminomethyl)-6-chlorocoumarin 53c54 
  
The procedure described for the synthesis of 3-(benzylaminomethyl)coumarin 53a was 
followed, using 6-chloro-3-(chloromethyl)coumarin 42c (0.84g, 4mmol) and 
benzylamine (0.76ml) in THF (8ml). Work-up and chromatography afforded 3-
(benzylaminomethyl)-6-chlorocoumarin 53c as a yellow solid (0.71g, 64%), m.p. 106-
109oC (lit.54 106-110); ν
max  
(nujol)/cm-1
 
3429 (NH) and 1704 (C=O); δH (400 MHz; 
CDCl3) 2.00 (1H, br s, NH), 3.74 (2H, 1’-CH2), 3.84 (2H, s, CH2Ph), 7.24-7.43 (8H, 
series of multiplets, Ar-H) and 7.65 (1H, s, 4-H); δC (100 MHz; CDCl3) 48.2 and 53.3 (2 
x CH2), 117.9, 120.3, 126.8, 127.2, 128.1, 128.5, 128.9, 129.6, 130.8, 137.8, 139.6 and 
151.5  (Ar-C) and 160.8 (C=O). 
 
                                     
O O
N
H
Br
 
                           3-(Benzylaminomethyl)-6-bromocoumarin 53d54  
 
The procedure described for the synthesis of 3-(benzylaminomethyl) coumarin 53a was 
followed, using 6-bromo-3-(chloromethyl)coumarin 42d (0.27g, 1mmol) and 
benzylamine (0.21ml) in THF (6ml). Work-up and chromatography [on silica gel; elution 
with CHCl3-EtOAc (4:1)] afforded 3-(benzylaminomethyl)-6-bromocoumarin as a pale 
yellow solid 53d (0.114g, 35%); m.p 107-110oC (lit.54 106-110oC); ν
max 
(nujol)/cm-1 
 
3326 (NH) and 1723 (C=O); δH (400 MHz; CDCl3) 1.85 (1H, br s, NH), 3.74 (2H, 1’-
CH2), 3.84 (2H, s, CH2Ph), 7.19-7.34 (6H, series of multiplets, Ar-H) and 7.55-7.59 (2H, 
m, Ar-H) and 7.65 (1H, s, 4H); δC (100 MHz; CDCl3) 48.2 and 53.2 (2xCH2), 117.0, 
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118.2, 120.8, 127.2, 128.1, 128.5, 128.9, 129.8, 133.7, 137.7, 139.6 and 152.0 (Ar-C) and 
160.7 (C=O). 
                                     
O O
N
H
O
 
                                 3-(Benzylaminomethyl)-8-methoxycoumarin 53e54 
 
The procedure described for the synthesis of 3-(benzylaminomethyl) coumarin 53a was 
followed, using 3-methoxy-3-(chloromethyl)coumarin 42e (0.2g, 1mmol) and 
benzylamine (0.15ml) in THF (4ml). Work-up and chromatography [on silica gel; elution 
with CHCl3-EtOAc (4:1)] afforded 3-(benzylaminomethyl)-8-methoxycoumarin 53e as a 
pale yellow oil (0.19g, 73%); ν
max
(nujol) /cm-1 3448 (NH) and 1716 (C=O); δH (400 
MHz; CDCl3) 2.15 (1H, br s, NH), 3.72 (2H, s, 1’-CH2), 3.81 (2H, s, CH2Ph), 3.91 (3H, 
s, OCH3), 7.00 (2H, d, J = 8Hz, Ar-H), 7.14-7.33 (6H, series of multiplets, Ar-H) and 
7.66 (1H, s, 4-H); δc (100 MHz; CDCl3) 48.2 and 53.1 (2 x CH2), 56.1 (OCH3), 112.8, 
118.9, 119.8, 124.2, 127.0, 127.4, 128.0, 128.3, 139.3, 139.6, 142.6 and 146.9 (Ar-C) and 
160.8 (C=O).        
                         
3.2.7. Arbuzov reactions of 3-(halomethyl)coumarin products  
 
3.2.7.1. Optimisation Studies of Arbuzov reactions 
 
Experimental procedure 1 
To 3-(chloromethyl)coumarin 42a (0.35g, 1.3mmol) was added triethyl phosphite 
(0.40ml) and the mixture was boiled under reflux for 4 hours. Upon completion of the 
reaction, as monitored by TLC, the mixture was separated by flash column 
chromatography [on silica gel; elution with ethyl acetate-hexane (3:1)] to afford diethyl 
(3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48a as a yellow solid (0.318g, 60%) 
Experimental procedure 2 
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To 3-(chloromethyl)coumarin 42a (0.823g, 4.3mmol) was added triethyl phosphite 
(0.70ml) and the mixture was refluxed under nitrogen for 4 hours. Upon completion of 
the reaction, as monitored by TLC, the mixture was separated by flash column 
chromatography [on silica gel; elution with ethyl acetate-hexane (3:1)] to afford diethyl 
(3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48a as a yellow solid (0.236g, 16%) and 
diethyl [(2-oxo-2H-chromen-3-yl)methyl]phosphonate 49a as a brown oil (0.401g, 43%)  
Experimental procedure 3 
To 3-(iodomethyl)coumarin 41a (0.34g, 1.2mmol) was added triethyl phosphite (0.40ml) 
and the mixture was refluxed under nitrogen for 4 hours. Upon completion of the 
reaction, as monitored by TLC, the mixture was separated by flash column 
chromatography [on silica gel; elution with ethyl acetate-hexane (3:1)] to afford diethyl 
[(2-oxo-2H-chromen-3-yl) methyl]phosphonate 49a as a brown oil (0.215g, 61%). 
 
Experimental procedure 1 
                                                       
O O
P
OO
O
 
                             Diethyl (3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48a 
            
To 3-(chloromethyl)coumarin 42a (0.35g, 1.3mmol) was added triethyl phosphite 
(0.42ml) and the mixture was boiled under reflux for 4 hours. Upon completion of the 
reaction, as monitored by TLC, the mixture was separated by flash column 
chromatography [on silica gel; elution with ethyl acetate-hexane (3:1)] to afford diethyl 
(3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48a as a yellow solid (0.318g, 60%); 
(Found M+: 296.082484. C14H17O5P requires M: 296.081362); m.p. 47-49oC; νmax 
(nujol)/cm-1 1240 (P=O) and 1734 (C=O); δH (400 MHz; CDCl3) 1.33 (6H, t, J = 7Hz, 2 x 
CH2CH3), 2.60 (3H, d, J = 3.2Hz, CH3), 4.12 and 4.26 (4H, 2 x m, 2 x CH2OP), 7.25 (2H, 
m, Ar-H), 7.44 (1H, t, J = 8.4Hz, Ar-H) and 8.50 (1H, s, Ar-H); δC (100 MHz; CDCl3) 
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14.7 (Ar-OCH2CH3), 16.2 (CH3), 16.3 (d, JP,C = 6.1Hz, 2 x CH2CH3), 62.8 (d, JP,C = 
5.5Hz, 2 x CH2OP), 116.7, 118.2, 124.2, 128.0, 130.6, 137.4 and 152.0 (Ar-C), 135.6 (d, 
JP,C = 12Hz, C-4) and 161.1 (C=O); m/z 296 (M+1, 100%). 
 
 
                                                  
O O
O
P
OO
O
 
       Diethyl (8-ethoxy-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48b 
The procedure described in experimental procedure 3 for the synthesis of 48a was 
followed using 3-(chloromethyl)-8-ethoxycoumarin 42b (0.25g, 1.2mmol) and triethyl 
phosphite (0.35ml). Work-up and chromatography [elution with ethyl acetate-hexane 
(1:3)] afforded diethyl (8-ethoxy-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48b as a 
pale yellow solid (0.186g, 52%); (Found M+: 340.106262. C16H21O6P requires M: 
340.107577); m.p. 42-45oC; ν
max 
(nujol)/cm-1 1260 (P=O) and 1709 (C=O); δH (400 
MHz; CDCl3) 1.30 (6H, t, J = 7.2Hz, 2 x OCH2CH3), 1.45 (3H, t, J = 7Hz, Ar-
OCH2CH3), 2.59 (3H, d, J = 3.2Hz, CH3), 4.10-4.27 (6H, m, 2 x CH2OP and 1 x Ar-
OCH2CH3), 7.00 (1H, d, J = 8 Hz, Ar-H), 7.13 (1H, t, J = 8.2Hz, Ar-H) and 8.03 (1H, d, 
J = 8.4Hz, Ar-H); δC (100 MHz; CDCl3) 14.7 (Ar-OCH2CH3), 16.3 (1 x CH3), 16.4 (d, 
JP,C = 6.2Hz, 2 x OCH2CH3), 62.7 (d, JP,C = 5.5Hz, 2 x CH2OP), 65.0 (Ar-OCH2CH3), 
114.0, 118.8, 119.3, 123.6, 137.5, 142.2 and 146.3 (Ar-C), 135.8 (d, JP,C = 11Hz, C-4) 
and 160.6 (C=O). 
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    Diethyl (6-chloro-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48c 
 
The procedure described in experimental procedure 3 for the synthesis of 48a was 
followed using 6-chloro-3-(chloromethyl)coumarin 42c (0.21g, 1.1mmol) and triethyl 
phosphite (0.30ml). Work-up and chromatography [elution with ethyl acetate-hexane 
(1:3)] afforded diethyl (6-chloro -3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48d as a 
pale yellow solid (0.26g, 68%); (Found M+: 330.042192. C14H16ClO5P requires M: 
330.042390); m.p. 76-78oC; νmax (nujol)/cm-1 1255 (P=O) and 1730 (C=O); δH (400 
MHz; CDCl3) 1.32 (6H, t, J = 7Hz, 2 x CH2CH3), 2.57 (3H, d, J = 3.2Hz, CH3), 4.11 and 
4.31 (4H, m, 2 x CH2OP), 7.19 (1H, d, J = 8.8Hz, Ar-H), 7.38 (1H, dd, J = 8.8 Hz, Ar-H) 
and 8.52 (1H, d, J = 2.4 Hz, Ar-H); δC (100 MHz; CDCl3) 16.3 (1 x CH3), 16.5 (d, JP,C = 
6.2Hz, 2 x OCH2CH3), 63.0 (d, JP,C = 5.6Hz, 2 x CH2OP), 117.9, 119.1, 127.5, 129.7, 
130.7, 134.8 and 150.4 (Ar-C), 136.6 (d, JP,C = 10Hz, C-4) and 160.5 (C=O); m/z 330 
(M+1, 100%).                                   
                                           
O O
P
OO
O
Br
 
                          Diethyl (6-bromo-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48d 
 
The procedure described in experimental procedure 3 for the synthesis of 48a was 
followed using 6-bromo-3-(chloromethyl)coumarin 42d (0.35g, 1,2mmol) and triethyl 
phosphite (0.42ml). Work-up after chromatography [elution with ethyl acetate-hexane 
(1:3)] afforded diethyl (6-bromo-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48d as a 
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yellow solid (0.31g, 65%) (Found M+: 373.989683. C14H16BrO5P requires M: 
373.991873); m.p. 77-79oC; ν
max 
(nujol)/cm-1 1240 (P=O) and 1734 (C=O); δH (400 
MHz; CDCl3) 1.34 (6H, t, J = 7.2Hz, 2 x CH2CH3), 2.59 (3H, d, J = 3.2Hz, CH3), 4.16 
and 4.26 (4H, 2 x m, 2 x CH2OP), 7.15 (1H, d, J = 8.8Hz, Ar-H), 7.54 (1H, dd, J = 
8.8Hz, Ar-H) and 8.69 (1H, s, Ar-H); δC (100 MHz; CDCl3) 16.3 (CH3), 16.6 (d, JP,C = 
6.1Hz, 2 x OCH2CH3), 63.1 (d, JP,C = 5.5Hz, 2 x CH2OP), 117.2, 118.3, 119.6, 130.6, 
133.5, 134.9 and 150.8 (Ar-C), 136.6 (d, JP,C = 10Hz,C-4) and 160.3 (C=O); m/z 374 
(M+1, 95%) and 379 (100%). 
   
Experimental procedure 2                                        
                       
O O
P
O
O
O
                                
O O
P
OO
O
  
Diethyl [(2-oxo-2H-chromen-3-yl)methyl]phosphonate 49a and diethyl (3-methyl-2-oxo-
2H-chromen-4-yl)phosphonate 48a                                                                                      
 
To 3-(chloromethyl)coumarin 42a (0.823g, 4.3mmol) was added triethyl phosphite 
(1.4ml) and the mixture was refluxed under nitrogen for 4 hours. Upon completion of the 
reaction, as monitored by TLC, the mixture was then separated by flash column 
chromatography [on silica gel; elution with ethyl acetate-hexane (3:1)] to afford two 
fractions. 
 
Fraction 1: diethyl (3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48a as a pale yellow 
solid (0.236g, 16%). 
 
Fraction 2: diethyl [(2-oxo-2H-chromen-3-yl)methyl]phosphonate 49a as a pale brown 
oil (0.401g, 43%); (Found M+: 296.3079819. C14H17O5P requires M: 296.081362); νmax 
(nujol)/cm-1 1240 (P=O) and 1734 (C=O); δH (400 MHz; CDCl3) 1.28 (6H, t, J =7 Hz, 2 x 
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OCH2CH3), 3.18 (2H, d, JP,H= 22Hz, CH2P), 4.10 (4H, q, J = 4.3Hz, 2 x CH2OP), 7.26-
7.51 (4H, series of multiplets, Ar-H) and 7.82 (1H, d, JP,C = 4.4Hz, 4-H); δC (100 MHz; 
CDCl3) 16.3 (d, JP,C = 6.2Hz, 2 x OCH2CH3), 26.7 (d, JP,C= 139Hz, CH2P), 62.4 (d, JP,C = 
6.6Hz, 2 x CH2OP), 116.4, 119.1, 120.2, 124.4, 127.6, 131.2, 141.7, and 153.2 (Ar-C) 
and 161.1 (C=O); m/z 296 (M+1, 90%) and 160 (100%).                                    
                   
O O
P
O
O
O
O
                                    
O
O O
P
OO
O
              
Diethyl [(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49b and diethyl (8-
ethoxy-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48b 
 
                                                                         
The procedure described in experimental procedure 2 for the synthesis of compounds 48a 
and 49a was followed using 8-ethoxy-3-(chloromethyl)coumarin 42b (0.86g, 3.6mmol) 
and triethyl phosphite (1.2ml). Work-up and chromatography [on silica gel; elution with 
ethyl acetate-hexane (1:3)] afforded two fractions. 
 
Fraction 1: diethyl (8-ethoxy-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate as a pale 
yellow crystals, 48b (0.174g, 18%). 
  
 Fraction 2: diethyl [(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49b as a 
pale yellow solid (0.83g, 85%); (Found M+: 340.107526. C16H21O6P requires M: 
340.107526); m.p. 53-56oC; ν
max 
(nujol)/cm-1 1258 (P=O) and 1724 (C=O); δH (400 
MHz; CDCl3) 1.24 (6H, t, J = 7Hz, 2 x OCH2CH3), 1.43 (3H, t, J = 6.8Hz, Ar-
OCH2CH3), 3.11 (2H, d, JP,H = 20Hz, CH2P), 4.07 (6H, m, 2 x CH2OP and 1 x Ar-
OCH2CH3), 7.27 (2H, dd, J = 4.6Hz, Ar-H), 7.11 (1H, t, J = 7.8Hz, Ar-H) and 7.74 (1H, 
d, JP,C = 4.4Hz, 4-H); δC (100 MHz; CDCl3) 14.6 (Ar-OCH2CH3), 16.3 (d, JP,C= 6.1Hz, 2 
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x OCH2CH3), 26.6 (d, JP,C = 139Hz, CH2P), 62.4 (d, JP,C = 6.5Hz, 2 x CH2OP), 64.9 (Ar-
OCH2CH3), 114.5, 119.0, 119.9, 120.3, 124.3, 142.0, 143.0 and 146.3 (Ar-C) and 160.8 
(C=O); m/z 340 (M+1, 100%).    
                 
  
O
Cl
O
P
O
O
O
                                                    
O O
P
OO
O
Cl
 
Diethyl [(6-chloro-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49c and diethyl (6-
chloro-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48c   
                                             
The procedure described in experimental procedure 2 for the synthesis of compounds 48a 
and 49a was followed using 6-chloro-3-(chloromethyl)coumarin 42c (0.81g, 3.5mmol) 
and triethyl phosphite (1.2ml). Work-up and chromatography [on silica gel; elution with 
ethyl acetate-hexane (1:3)] afforded two fractions. 
 
Fraction 1: diethyl (6-chloro-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48c as a 
pale yellow solid (0.12g, 10%). 
                              
Fraction 2: diethyl [(6-chloro-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49c as a 
yellow solid (0.61g, 53%); (Found M+: 330.042081.
 
C14H16ClO5P requires M: 
330.012390); m.p. 72-74oC; ν
max 
(nujol)/cm-1
 
1260 (P=O) and 1725 (C=O); δH (400 MHz; 
CDCl3) 1.29 (6H, t, J = 7.2Hz, 2 x OCH2CH3), 3.15 (2H, d, JP,H= 22Hz, CH2P), 4.10 (4H, 
m, JP,H  = 6.8Hz, 2 x CH2OP), 7.27 (1H, s, Ar-H), 7.44 and 7.47 (2H, 2 x s, Ar-H) and 
7.75 (1H, d, JP,C = 4Hz, 4-H); δC (100 MHz; CDCl3) 16.3 (d, JP,C = 6.1Hz, 2 x CH2CH3), 
26.8  (d, 
 
JP,C = 139Hz, CH2P), 62.5 (d, JP,C = 6.5Hz, 2 x CH2OP), 117.9, 120.1, 121.6, 
126.8, 129.7, 131.2, 140.4, 151.5 (Ar-C) and 161.3 (C=O); m/z 330 (M+1, 80%) and 109 
(100%). 
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Diethyl [(6-bromo-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49d and diethyl (6-
bromo-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48d   
 
The procedure described in experimental procedure 2 for the synthesis of 48a and 49a 
was followed using 6-bromo-3-(chloromethyl)coumarin 42d (1.05g, 4.0mmol) and 
triethyl phosphite (1.3ml). Work-up and chromatography [on silica gel; elution with ethyl 
acetate-hexane (1:3)] afforded two fractions.  
 
Fraction1: diethyl (6-bromo-3-methyl-2-oxo-2H-chromen-4-yl)phosphonate 48d as a 
yellow solid (0.12g, 8%). 
 
 Fraction 2: diethyl [(6-bromo-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49d as a 
pale brown oil (0.761g, 53%); (Found M+: 373.014356. C14H16BrO5P requires M: 
373.010978); ν
max 
(nujol)/cm-1
 
 1260 (P=O) and 1725 (C=O); δH (400 MHz; CDCl3) 1.28 
(6H, t, J = 7.2Hz, 2 x CH2CH3), 3.15 (2H, d, JP,H = 22Hz, CH2P), 4.10 (4H, q, J = 6.8Hz, 
2x CH2OP), 7.27-7.45 (3H, series of multiplets, Ar-H) and 7.74 (1H, d, JP,C = 6.1Hz, 4-
H); δC (100 MHz; CDCl3) 16.9 (d, JP,C = 6.1Hz, 2 x OCH2CH3), 27.5 (d, JP,C = 139Hz, 
CH2P), 62.4 (d, JP,C = 6.1Hz, 2 x CH2OP), 118.5, 120.8, 122.3, 127.5, 130.4, 131.9, 
141.1, and 152.2 (Ar-C) and 161.2 (C=O); m/z 376 (M+1, 70%) and 109 (100%). 
 
  Experimental procedure 3 
                                           
O O
P
O
O
O
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                              Diethyl [(2-oxo-2H-chromen-3-yl)methyl]phosphonate 49a 
 
To 3-(iodomethyl)coumarin 41a (0.35g, 1.2mmol) was added triethyl phosphite (0.40ml) 
and the mixture was refluxed under nitrogen for 4 hours. After completion of the 
reaction, as monitored by TLC, the mixture was separated by flash column 
chromatography [on silica gel; elution with ethyl acetate-hexane (3:1)] to afford diethyl 
[(2-oxo-2H-chromen-3-yl)methyl]phosphonate 49a as a brown oil (0.22g, 61%). 
 
                                          
O O
P
O
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                     Diethyl [(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49b 
 
The procedure described in experimental procedure 3 for the synthesis of compound 41a 
was followed using 8-ethoxy-3-(iodomethyl)coumarin 41b (0.42g, 1.2mmol) and triethyl 
phosphite (0.40ml). Work-up and chromatography [on silica gel; elution with ethyl 
acetate-hexane (1:3)] afforded diethyl [(8-ethoxy-2-oxo-2H-chromen-3-
yl)methyl]phosphonate 49b as a yellow solid (0.172g, 40%). 
                                 
O
Cl
O
P
O
O
O
 
              Diethyl [(6-chloro-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49c 
 
The procedure described in experimental procedure 3 for the synthesis of compound 41a 
was followed using 6-chloro-3-(iodomethyl)coumarin 41c (0.421g, 1.3mmol) and triethyl 
phosphite (0.44ml). Work-up and chromatography [on silica gel; elution with ethyl 
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acetate-hexane (1:3)] afforded as a yellow solid diethyl [(6-chloro-2-oxo-2H-chromen-3-
yl)methyl]phosphonate 49c as a yellow solid (0.234g, 54%). 
 
                                 
O
Br
O
P
O
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O
 
            Diethyl [(6-bromo-2-oxo-2H-chromen-3-yl)methyl]phosphonate 49d 
 
The procedure described in experimental procedure 3 for the synthesis of compound 49a 
was followed using 6-bromo-3-(iodomethyl)coumarin 41d (0.423g, 1.2mmol) and 
triethyl phosphite (0.40ml). Work-up and chromatography [on silica gel; elution with 
ethyl acetate-hexane (1:3)] afforded diethyl [(6-bromo-2-oxo-2H-chromen-3-
yl)methyl]phosphonate 49d as a brown oil (0.172g, 40%). 
                     
3.2.8. Acetylation of 3-(benzylaminomethyl)coumarin derivatives 
                                        
Br
O
N
O
O
Cl
    
 
            N-Benzyl-2-bromo-N-[(6-chloro-2-oxo-2H-chromen-3-yl)methyl]acetamide 55d† 
 
To 3-[(benzylamino)methyl]-6-bromocoumarin (0.49g, 1.4mmol) and chloroacetyl 
chloride (0.32ml, 2mmol) in THF (6ml) were added.60 The mixture was refluxed at 100-
110oC under nitrogen for 45 minutes, and the resulting solution was allowed to cool to 
room temperature. Crystallization from ethanol afforded N-benzyl-2-bromo-N-[(6-
chloro-2-oxo-2H-chromen-3-yl)methyl]acetamide 55d as a white solid (0.34g, 56%); 
(Found M+: 418.990988. C19H15BrClNO3 requires M: 418.992382); m.p. 109-111oC; νmax 
(nujol)/cm-1
 
O-C=O (1721) and N-C=O (1658); δH (400 MHz; DMSO-d6) 4.27-4.71 (6H, 
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series of signals, 3 x CH2), 7.23-7.80 (8H, overlapping multiplets, Ar-H) and 7.99 (1H, s, 
4-H); m/z 421 (M+1, 18%) and 182 (100%). 
                                
O
N
O
Cl
O
Cl
 
            N-Benzyl-2-chloro-N-[(6-chloro-2-oxo-2H-chromen-3-yl)methyl]acetamide 55c† 
 
The procedure described for the synthesis of compound 55d was followed using 3-
[(benzylamino)methyl]-6-chlorocoumarin 53c (0.18g, 0.6mmol) and chloroacetyl 
chloride (0.13ml, 1.2mmol) in THF (4ml). Crystallization from ethanol afforded N-
benzyl-2-chloro-N-[(6-chloro-2-oxo-2H-chromen-3-yl)methyl]acetamide 55c as a white 
solid (0.156g, 70%); (Found M+: 377.040222. C19H15Cl2NO3 requires M: 377.039949); 
m.p. 120-122oC; ν
max 
(nujol)/cm-1
 
O-C=O (1721) and N-C=O (1658); δH (400 MHz; 
CDCl3) 4.17-4.45 (6H, series of signals, 3 x CH2), 7.27-7.48 (8H, overlapping multiplets, 
Ar-H), 7.74 (1H, s, 4-H); m/z 377 (M+1, 13%) and 91 (100%). 
 
                                   
O
N
O
O
Cl
 
          N-benzyl-2-chloro-N-[(2-oxo-2H-chromen-3-yl)methyl]acetamide 55a† 
 
The procedure described for the synthesis of compound 55d was followed using 3-
[(benzylamino)methyl]coumarin 53a (0.35g, 1.3mmol) and chloroacetyl chloride 
(0.30ml, 2.6mmol) in THF (6ml). Crystallization from ethanol afforded N-benzyl-2-
chloro-N-[(2-oxo-2H-chromen-3-yl)methyl]acetamide 55a as a white solid (0.29g, 64%);  
 
† 13C data not cited due to multiplicity of signals arising from rotamers at 30oC. 
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(Found M+: 341.083861. C19H16ClNO3 requires M: 341.081871); m.p. 98-100oC; νmax 
(nujol)/cm-1 O-C=O (1721) and N-C=O (1658); δH (400 MHz; CDCl3) 4.15-4.45 ((6H, 
series of signals, 3 x CH2), 7.23-7.57 (9H, overlapping multiplets, Ar-H) and 7.84 (1H, s, 
4-H); m/z 341 (M+1, 22%) and 182 (100%); m/z 385 (M+1, 25%) and 182 (100%). 
                                                                       
O
N
O
O
Cl
O
 
          N-benzyl-2-chloro-N-[(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]acetamide 55b† 
 
The procedure described for the synthesis of compound 55d was followed using 3-
[(benzylamino)methyl]-8-ethoxycoumarin 53b (0.54g, 1.7mmol) and chloroacetyl 
chloride (0.4ml, 4mmol) in THF (8ml). Chromatography [elution with ethyl acetate-
hexane (1:4)] afforded N-benzyl-2-chloro-N-[(8-ethoxy-2-oxo-2H-chromen-3-
yl)methyl]acetamide 55b as a brown oil (0.48g, 72%); (Found M+: 385.108324. 
C21H20ClNO4 requires M: 385.980888); νmax (nujol)/cm-1
 
O-C=O (1721) and N-C=O 
(1658); δH (400 MHz; DMSO-d6): 1.38 (3H, t, J = 6.6Hz, OCH2CH3), 4.17 (2H, q, J = 
6.8Hz, OCH2CH3), 4.17-4.59 (6H, series of signals, 3 x CH2), 7.26-7.38 (8H, overlapping 
multiplets, Ar-H) and 7.78 (1H, s, 4-H); m/z 385 (M+1, 25%) and 182 (100%). 
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3.2.9. Arbuzov reactions of chloroacetamide derivatives  
                                  
O O
N
O
PBr
O
O
O
  
Diethyl N-benzyl-N-[(6-bromo-2-oxo-2H-chromen-3-yl)methyl]carbamoylmethylphos-
phonate 56d‡ 
 
To N-benzyl-2-chloro-N-[(6-bromo-2-oxo-2H-chromen-3-yl)methyl]acetamide 55d 
(0.157g, 0.4mmol) was added triethyl phosphite (0.2ml, 0.8mmol) and the mixture was 
refluxed under nitrogen for 4 hours and then allowed to cool to room temperature. The 
crude product was isolated by flash chromatography [on silica gel; elution with ethyl 
acetate-hexane (1:2)] to afford diethyl N-benzyl-N-[(6-bromo-2-oxo-2H-Chromen-3-
yl)methyl]carbamoylmethylphosphonate 56d as a pale yellow solid (0.168g, 86%); 
(Found M+: 521.058999. C23H25BrNO6P requires M: 521.060287); m.p. 137-139oC; νmax 
(nujol)/cm-1
 
O-C=O (1721), N-C=O (1658) and 1244 (P=O); (400 MHz; CDCl3) 1.32 
(6H, overlapping triplets, J = 7Hz, 2 x OCH2CH3), 3.10 (2H, d, JP,H = 22Hz, CH2P), 4.17 
(2H, overlapping multiplets, 2 x CH2OP), 4.50 and 4.83 (4H, 2 x s, 2 x CH2N), 7.19-7.60  
 (7H, m, Ar-H), 7.67 (1H, s, Ar-H), and 7.93 (1H, s, 4-H); δC (100 MHz; CDCl3) 16.3 (d, 
JP,C = 6.2Hz, 2 x OCH2CH3), 33.6 (d, JP,C = 140Hz, CH2P), 45.9 and 52.8 (2 x CH2N), 
62.9 (d, JP,C = 6.4Hz, 2 x CH2OP), 117.0, 118.0, 120.9, 124.2, 126.2, 127.9, 128.7, 129.1, 
130.2, 133.9, 135.7, 138.0 and 151.9 (Ar-C), 160.5 and 166.2 (C=O); m/z 523 (M+1, 
16%) and 106 (100%). 
 
 
 
 
 
 
‡ 13C data cited for major rotamer. 
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Diethyl N-benzyl-N-[(6-chloro-2-oxo-2H-chromen-3-yl)methyl]carbamoylmethylphos-
phonate 56d 
 
 
The procedure described for the synthesis of compound 56d was followed using N-
benzyl-2-chloro-N-[(6-chloro-2-oxo-2H-chromen-3-yl)methyl]acetamide 55c (0.46g, 
1.2mmol) and triethyl phosphite (0.40ml, 2mmol). Chromatography and afforded diethyl 
N-benzyl-N-[(6-chloro-2-oxo-2H-chromen-3-yl)methyl]carbamoylmethylphosphonate 
56d as a yellow solid (0.455g, 77%) m.p. 165-167oC; (Found M+: 477.111852. 
C23H25ClNO6P requires M: 477.110804); νmax (nujol)/cm-1 O-C=O (1721), N-C=O (1658) 
and 1244 (P=O); (400 MHz; CDCl3) 1.35 (6H, overlapping triplets, 2 x OCH2CH3), 3.14 
(2H, d, JP,H= 22Hz, CH2P), 4.09 (4H, overlapping multiplets, 2 x CH2OP), 4.55 and 4.87 
(4H, 2 x s, 2 x CH2N), 7.27-7.49 (7H, m, Ar-H), 7.56 (1H, s, 10-H) and 7.93 (1H, s, 4-H); 
δC (100 MHz; CDCl3) 16.3 (d, JP,C = 6.2Hz, 2x OCH2CH3), 33.6 (d, JP,C = 130Hz, CH2P), 
45.9 and 52.8 (2 x CH2N), 62.9 (d, JP,C = 6.5Hz, 2 x CH2OP) 117.8, 120.4, 124.9, 126.2, 
127.2, 127.9, 128.7, 129.1, 129.7, 131.1, 135.8, 138.1 and 151.4 (Ar-C), 160.6 and 166.2 
(C=O); m/z 477 (M+1, 10%) and 106 (100%) . 
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Diethyl N-benzyl-N-[(2-oxo-2H-chromen-3-yl)methyl]carbamoylmethylphosphonate 56a 
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The procedure described for the synthesis of compound 56d was followed using N-
benzyl-2-chloro-N-[(2-oxo-2H-chromen-3-yl)methyl]acetamide 55a (0.16g, 0.5mmol) 
and triethyl phosphite (0.2ml, 0.9mmol). Chromatography and afforded diethyl N-benzyl-
N-[(2-oxo-2H-chromen-3-yl)methyl]carbamoylmethylphosphonate 56a as a yellow solid 
(0.134g, 60%); (Found M+: 443.152637. C23H26NO6P requires M: 443.149776); m.p. 
138-140oC; ν
max 
(nujol)/cm-1:
 
O-C=O (1721), N-C=O (1658) and 1244 (P=O); (400 MHz; 
CDCl3) 1.31 (6H, overlapping triplets, 2 x OCH2CH3), 3.10 (2H, d, JP,H = 22Hz, CH2P), 
4.09 (2H, overlapping signals, 2 x CH2OP), 4.51 and 4.85 (4H, 2 x s, 2 x CH2N), 7.22-
7.67 (9H, overlapping multiplets, Ar-H) and 7.98 (1H, s, 4-H); δC (100 MHz; CDCl3) 
16.3 (d, JP,C = 6.3Hz, 2 x OCH2CH3), 33.6 (d, JP,C = 130Hz, CH2P), 45.8 and 52.7 (2 x 
CH2N), 62.9 (d, JP,C = 6.6Hz, 2 x CH2OP), 116.3, 119.3, 123.5 124.4, 126.2, 128.0, 
128.7, 129.1, 131.2, 135.9, 139.6 and 153.1 (Ar-C), 161.3 and 166.1 (C=O);  m/z 443 
(M+1, 10%) and 106 (100%). 
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Diethyl N-benzyl-N-[(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]carbamoylmethylphos-
phonate 56d 
 
 
 
The procedure described for the synthesis of compound 56d was followed using N-
benzyl-2-chloro-N-[(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]acetamide 55b (0.30g, 
0.8mmol) and triethyl phosphite (0.26ml, 2mmol). Chromatography and afforded diethyl 
N-benzyl-N-[(8-ethoxy-2-oxo-2H-chromen-3-yl)methyl]carbamoylmethylphosphonate 
56d as a brown oil (0.19g, 77%); (Found M+: 487.174816. C25H30NO7P requires M, 
487.175991); ν
max 
(nujol)/cm-1 O-C=O (1721), N-C=O (1658) and 1244 (P=O); (400 
MHz; CDCl3) 1.28 (6H, overlapping triplets, 2 x OCH2CH3), 1.46 (3H, t, J = 7Hz, Ar-
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OCH2CH3), 3.1 (2H, d, JP,H = 22Hz, CH2P), 4.17 (6H, overlapping multiplets, 2 x CH2OP 
and Ar-OCH2CH3), 4.50 and 4.82 (4H, 2 x s, 2 x CH2N), 7.10-7.43 (8H, overlapping 
multiplets, Ar-H), 7.92 (1H, s, 4-H); δC (100 MHz; CDCl3) 14.7 (Ar-OCH2CH3), 16.3 (d, 
JP,C = 4.2Hz, 2 x OCH2CH3), 27.4 (d, JP,C = 298Hz, CH2P), 45.8 and 52.7 (2 x CH2N), 
62.8 (d, JP,C = 4.3Hz, 2 x CH2OP), 65.0 (Ar-OCH2CH3), 119.5, 120.1, 124.2, 124.6, 
126.3; 127.9, 128.0, 128.7, 129.1, 136.0, 139.8 and 146.3 (Ar-C), 160.9 and 166.1 
(C=O); m/z 487 (M+1, 24%) and 106 (100%). 
 
3.2.10. Computer Docking 
The Accelrys Cerius 2 software package was run on an SGI O2 platform. The Universal 
forcefield was used as a default setting. The structures were drawn using the 3D sketcher 
on the visualizer, cleaned, energy-minimised and saved in MSI format. The HIV-1 
protease enzyme containing ritonavir was downloaded from the protein data bank.86 
Ritonavir was removed using the protein tools module and structure based options were 
used to dock the ligand into the active site of the enzyme. The docking, van der Waals’ 
and Ligandfit scores were recorded.     
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